{"title": "PDF", "author": "PDF", "url": "https://dgpi.de/wp-content/uploads/2014/11/2014-rotavirus-impfung-neugenorene.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "1\u00a0\n\u00a0Stellungnahme \tzur\tRotavirus \u2010Impfung \tvon\tFr\u00fch\u2010\tund\tNeugeborenen \tim\t\nstation\u00e4ren \tUmfeld\t\t\n\u00a0\nGemeinsame \u00a0Stellungnahme \u00a0der\u00a0St\u00e4ndigen \u00a0Impfkommission \u00a0(STIKO),\u00a0der\u00a0Deutschen \u00a0Akademie \u00a0f\u00fcr\u00a0\nKinder\u2010\u00a0und\u00a0Jugendmedizin \u00a0e.\u00a0V.\u00a0(DAKJ)\u00a0und\u00a0der\u00a0Gesellschaft \u00a0f\u00fcr\u00a0Neonatologie \u00a0und\u00a0P\u00e4diatrische \u00a0\nIntensivmedizin \u00a0e.\u00a0V.\u00a0(GNPI)\u00a0\n\u00a0\nZusammenfassung \t\nBei\u00a0den\u00a0in\u00a0Deutschland \u00a0zugelassenen \u00a0Rotavirus \u00a0(RV)\u2010Impfstoffen \u00a0Rotarix\u00ae\u00a0und\u00a0RotaTeq\u00ae \u00a0handelt\u00a0es\u00a0\nsich\u00a0um\u00a0orale\u00a0Lebendimpfstoffe. \u00a0Es\u00a0ist\u00a0m\u00f6glich,\u00a0dass\u00a0durch\u00a0die\u00a0Ausscheidung \u00a0von\u00a0Impfviren \u00a0im\u00a0Stuhl\u00a0\nnach\u00a0erfolgter\u00a0Impfung\u00a0eine\u00a0f\u00e4kal\u2010orale\u00a0\u00dcbertragung \u00a0auf\u00a0ungesch\u00fctzte \u00a0Kontaktpersonen \u00a0im\u00a0Umfeld\u00a0\nstattfindet \u00a0und\u00a0dadurch\u00a0bei\u00a0Risikokindern \u00a0m\u00f6glicherweise \u00a0ein\u00a0geringes\u00a0Erkrankungsrisiko \u00a0besteht.\u00a0\nDaher\u00a0stellt\u00a0sich\u00a0die\u00a0Frage,\u00a0ob\u00a0im\u00a0Krankenhaus \u00a0bei\u00a0Fr\u00fchgeborenen \u00a0oder\u00a0anderen\u00a0S\u00e4uglingen \u00a0RV\u2010\nImpfungen \u00a0erfolgen\u00a0sollten\u00a0bzw.\u00a0welche\u00a0hygienischen \u00a0Ma\u00dfnahmen \u00a0bei\u00a0Aufnahme \u00a0eines\u00a0vor\u00a0kurzem\u00a0\ngegen\u00a0RV\u00a0geimpften \u00a0S\u00e4uglings \u00a0notwendig \u00a0sind.\u00a0\nDie\u00a0folgende\u00a0Stellungnahme \u00a0ber\u00fccksichtigt \u00a0verschiedene \u00a0Gesichtspunkte, \u00a0die\u00a0im\u00a0anschlie\u00dfenden \u00a0\nBegr\u00fcndungstext \u00a0ausf\u00fchrlich \u00a0ausgef\u00fchrt \u00a0werden:\u00a0\n\uf0b7 Fr\u00fchgeborene \u00a0haben\u00a0im\u00a0Vergleich \u00a0zu\u00a0Reifgeborenen \u00a0ein\u00a0erh\u00f6htes\u00a0Risiko,\u00a0im\u00a01.\u00a0Lebensjahr \u00a0an\u00a0\neiner\u00a0RV\u2010Infektion\u00a0schwer\u00a0zu\u00a0erkranken. \u00a0\n\uf0b7 Hospitalisierte \u00a0S\u00e4uglinge, \u00a0einschlie\u00dflich \u00a0Fr\u00fchgeborene, \u00a0unterliegen \u00a0dem\u00a0Risiko\u00a0einer\u00a0\nnosokomialen \u00a0RV\u2010Gastroenteritis \u00a0(RVGE).\u00a0\u00a0\n\uf0b7 Die\u00a0RV\u2010Impfung\u00a0ist\u00a0nur\u00a0in\u00a0einem\u00a0kurzen\u00a0Zeitfenster \u00a0(6\u00a0bis\u00a0maximal\u00a024\u00a0bzw.\u00a032\u00a0Lebenswochen) \u00a0\nm\u00f6glich\u00a0und\u00a0die\u00a01.\u00a0Impfung\u00a0sollte\u00a0mit\u00a012\u00a0Lebenswochen \u00a0erfolgt\u00a0sein.\u00a0Zum\u00a0Zeitpunkt \u00a0der\u00a0\nEntlassung \u00a0k\u00f6nnen\u00a0daher\u00a0Fr\u00fchgeborene, \u00a0die\u00a0f\u00fcr\u00a0einen\u00a0l\u00e4ngeren\u00a0Zeitraum\u00a0hospitalisiert \u00a0\nwaren,\u00a0nicht\u00a0mehr\u00a0zeitgerecht \u00a0geimpft\u00a0werden.\u00a0\n\uf0b7 RV\u2010Impfstoffe \u00a0haben\u00a0eine\u00a0hohe\u00a0Wirksamkeit \u00a0zur\u00a0Verhinderung \u00a0von\u00a0schweren \u00a0RVGE.\u00a0F\u00fcr\u00a0\nFr\u00fchgeborene \u00a0liegen\u00a0f\u00fcr\u00a0RotaTeq\u00ae \u00a0Daten\u00a0zur\u00a0klinischen \u00a0Wirksamkeit \u00a0und\u00a0f\u00fcr\u00a0Rotarix\u00ae\u00a0Daten\u00a0\nzur\u00a0Immunogenit\u00e4t \u00a0vor.\u00a0\n\uf0b7 RV\u2010Impfstoffe \u00a0besitzen\u00a0auch\u00a0bei\u00a0Fr\u00fchgeborenen \u00a0>32\u00a0SSW\u00a0ein\u00a0gutes\u00a0Sicherheitsprofil. \u00a0Die\u00a0\nStudienlage \u00a0f\u00fcr\u00a0sehr\u00a0unreife\u00a0Fr\u00fchgeborene \u00a0(Gestationsalter \u00a0von\u00a025\u00a0bis\u00a031\u00a0SSW)\u00a0ist\u00a0bisher\u00a0\njedoch\u00a0begrenzt. \u00a0\n\uf0b7 Zur\u00a0\u00dcbertragung \u00a0von\u00a0Impfviren \u00a0gibt\u00a0es\u00a0eine\u00a0prospektive \u00a0Studie.\u00a0Dar\u00fcber\u00a0hinaus\u00a0liegen\u00a0\nEinzelfallberichte \u00a0oder\u00a0Ergebnisse \u00a0aus\u00a0Monitoring \u2010Untersuchungen \u00a0bzw.\u00a0aus\u00a0Surveys\u00a0vor.\u00a0\u00a0\n\uf0b7 Die\u00a0Ausscheidung \u00a0von\u00a0Impfviren \u00a0ist\u00a0ein\u00a0h\u00e4ufiges\u00a0Ereignis\u00a0(bei\u00a086\u201090%\u00a0der\u00a0Geimpften \u00a0\nnachgewiesen \u00a0mittels\u00a0RT\u2010PCR\u00a0und\u00a0bei\u00a020\u201030%\u00a0nachgewiesen \u00a0mittels\u00a0EIA).\u00a0\n\u2010Die\u00a0Impfvirusausscheidung \u00a0ist\u00a0nach\u00a0der\u00a01.\u00a0Dosis\u00a0h\u00e4ufiger\u00a0nachweisbar \u00a0als\u00a0nach\u00a0\nFolgedosen, \u00a0und\u00a0die\u00a0maximale \u00a0Ausscheidung \u00a0wird\u00a0zwischen\u00a0dem\u00a06.\u00a0bis\u00a08.\u00a0Tag\u00a0erreicht.\u00a0\nDie\u00a0Virusmenge \u00a0im\u00a0Stuhl\u00a0ist\u00a0nach\u00a0Gabe\u00a0von\u00a0Rotarix\u00ae\u00a0gr\u00f6\u00dfer\u00a0als\u00a0nach\u00a0RotaTeq\u00ae. \u00a0\n\uf0b7 Die\u00a0\u00dcbertragung \u00a0von\u00a0Impfviren \u00a0auf\u00a0Dritte\u00a0ist\u00a0nicht\u00a0h\u00e4ufig,\u00a0da\u00a0die\u00a0erforderliche \u00a0Infektionsdosis \u00a0\nrelativ\u00a0hoch\u00a0ist.\u00a0Wenn\u00a0eine\u00a0\u00dcbertragung \u00a0stattfindet, \u00a0ist\u00a0die\u00a0Infektion\u00a0in\u00a0aller\u00a0Regel\u00a0\nasymptomatisch. \u00a0\n\uf0b7 Es\u00a0ist\u00a0nicht\u00a0ausgeschlossen, \u00a0dass\u00a0sich\u00a0nach\u00a0der\u00a0RotaTeq\u00ae \u2010Impfung\u00a0in\u00a0seltenen\u00a0F\u00e4llen\u00a0neue,\u00a0\nnicht\u00a0urspr\u00fcnglich \u00a0im\u00a0Impfstoff \u00a0enthaltene \u00a0Reassortanten \u00a0aus\u00a0den\u00a0verschiedenen \u00a0im\u00a02\u00a0\n\u00a0Impfstoff\u00a0enthaltenen \u00a0Impfviren \u00a0bilden\u00a0k\u00f6nnen\u00a0und\u00a0damit\u00a0wieder\u00a0pathogene \u00a0Virusvarianten \u00a0\nentstehen. \u00a0\n\uf0b7 Hygieneempfehlungen \u00a0zur\u00a0Verhinderung \u00a0einer\u00a0m\u00f6glichen \u00a0f\u00e4kal\u2010oralen\u00a0\u00dcbertragung \u00a0von\u00a0\nImpfviren \u00a0m\u00fcssen\u00a0nach\u00a0Impfung\u00a0von\u00a0S\u00e4uglingen \u00a0in\u00a0der\u00a0Klinik\u00a0strikt\u00a0umgesetzt \u00a0werden.\u00a0Dazu\u00a0\nz\u00e4hlen\u00a0neben\u00a0der\u00a0\u00fcblichen\u00a0H\u00e4ndedesinfektion \u00a0auch\u00a0Schutzkittel \u00a0und\u00a0Handschuhe \u00a0beim\u00a0\nWindelwechsel. \u00a0Die\u00a0verwendeten \u00a0H\u00e4nde\u2010\u00a0und\u00a0Fl\u00e4chendesinfektionsmittel \u00a0sollten\u00a0eine\u00a0\nWirksamkeit \u00a0gegen\u00fcber \u00a0Rotaviren \u00a0haben.\u00a0Eine\u00a0Kohortenisolierung \u00a0nach\u00a0Impfung\u00a0mehrerer \u00a0\nKinder\u00a0kann\u00a0entsprechend \u00a0den\u00a0r\u00e4umlichen \u00a0Gegebenheiten \u00a0in\u00a0Absprache \u00a0mit\u00a0den\u00a0zust\u00e4ndigen \u00a0\nHygienikern \u00a0erwogen\u00a0werden.\u00a0\n\uf0b7 Sog.\u00a0\u201eK\u00e4nguruhen\u201c \u00a0ist\u00a0mit\u00a0Windel\u00a0und\u00a0unter\u00a0Beachtung \u00a0der\u00a0H\u00e4ndehygiene \u00a0durch\u00a0die\u00a0Eltern\u00a0\nauch\u00a0nach\u00a0Impfung\u00a0m\u00f6glich.\u00a0\n\uf0b7 Dieser\u00a0Hygienestandard \u00a0muss\u00a0auch\u00a0bei\u00a0der\u00a0station\u00e4ren \u00a0Aufnahme \u00a0von\u00a0S\u00e4uglingen, \u00a0welche\u00a0in\u00a0\neinem\u00a0Zeitraum\u00a0von\u00a02\u00a0bis\u00a04\u00a0Wochen\u00a0zuvor\u00a0eine\u00a0RV\u2010Impfung\u00a0erhielten, \u00a0strikt\u00a0angewendet \u00a0\nwerden.\u00a0\n\t\nNach\u00a0Abw\u00e4gung \u00a0von\u00a0Nutzen\u00a0und\u00a0Risiken\u00a0der\u00a0RV\u2010Impfung\u00a0kann\u00a0die\u00a0zeitgerechte \u00a0RV\u2010Impfung\u00a0auch\u00a0\nf\u00fcr\u00a0hospitalisierte \u00a0Fr\u00fchgeborene \u00a0und\u00a0andere\u00a0reifgeborene \u00a0aber\u00a0station\u00e4r \u00a0versorgte \u00a0S\u00e4uglinge \u00a0\nentsprechend \u00a0ihrem\u00a0chronologischen \u00a0Alter\u00a0empfohlen \u00a0werden.\u00a0Der\u00a0Nutzen,\u00a0dass\u00a0hospitalisierte \u00a0\nS\u00e4uglinge \u00a0durch\u00a0die\u00a0RV\u2010Impfung\u00a0vor\u00a0einer\u00a0nosokomialen \u00a0RV\u2010Infektion\u00a0gesch\u00fctzt \u00a0werden,\u00a0\u00fcberwiegt \u00a0\ndeutlich\u00a0das\u00a0\u00e4u\u00dferst\u00a0geringe\u00a0Erkrankungsrisiko \u00a0anderer\u00a0hospitalisierter \u00a0Patienten \u00a0durch\u00a0die\u00a0denkbare \u00a0\n\u00dcbertragung \u00a0von\u00a0Impfviren. \u00a0Das\u00a0\u00dcbertragungsrisiko \u00a0von\u00a0Impfviren \u00a0ist\u00a0zudem\u00a0bei\u00a0konsequenter \u00a0\nAnwendung \u00a0der\u00a0auf\u00a0neonatologischen \u00a0Stationen \u00a0\u00fcblichen\u00a0Standardhygienema\u00dfnahmen \u00a0gering,\u00a0\nsodass\u00a0eine\u00a0RV\u2010Impfung\u00a0auch\u00a0in\u00a0Kinderkliniken \u00a0einschlie\u00dflich \u00a0ihrer\u00a0neonatologischen \u00a0und\u00a0\nallgemeinen \u00a0Intensivstationen \u00a0m\u00f6glich\u00a0ist.\u00a0Die\u00a0Entscheidung, \u00a0ob\u00a0hospitalisierte \u00a0S\u00e4uglinge \u00a0aufgrund\u00a0\nvon\u00a0tats\u00e4chlich \u00a0bestehenden \u00a0Kontraindikationen \u00a0oder\u00a0anderen\u00a0gesundheitlichen \u00a0oder\u00a0\nhygienetechnischen \u00a0Bedenken \u00a0nicht\u00a0geimpft\u00a0werden\u00a0k\u00f6nnen,\u00a0muss\u00a0individuell \u00a0getroffen \u00a0und\u00a0mit\u00a0den\u00a0\nEltern\u00a0der\u00a0betroffenen \u00a0Kinder\u00a0besprochen \u00a0werden.\u00a0\u00a0\n\u00a0\nF\u00fcr\u00a0Fr\u00fchgeborene \u00a0mit\u00a0einem\u00a0Gestationsalter \u00a0von\u00a025\u00a0bis\u00a031\u00a0SSW\u00a0ist\u00a0die\u00a0Datenlage \u00a0aus\u00a0den\u00a0\nZulassungsstudien \u00a0begrenzt, \u00a0so\u00a0dass\u00a0eine\u00a0individuelle \u00a0Risikoabw\u00e4gung \u00a0auch\u00a0unter\u00a0Ber\u00fccksichtigung \u00a0\ndes\u00a0gerade\u00a0in\u00a0dieser\u00a0Altersgruppe \u00a0erh\u00f6hten \u00a0Erkrankungsrisikos \u00a0durch\u00a0RV,\u00a0sinnvoll\u00a0erscheint. \u00a0Es\u00a0wird\u00a0\nerwartet, \u00a0dass\u00a0in\u00a0naher\u00a0Zukunft\u00a0erg\u00e4nzende \u00a0Informationen \u00a0zur\u00a0Sicherheit \u00a0und\u00a0Vertr\u00e4glichkeit \u00a0der\u00a0RV\u2010\nImpfung\u00a0von\u00a0Fr\u00fchgeborenen \u00a0verf\u00fcgbar \u00a0sein\u00a0werden.\u00a0Diesbez\u00fcgliche \u00a0Studien\u00a0werden\u00a0aktuell\u00a0in\u00a0\nAustralien, \u00a0England\u00a0und\u00a0den\u00a0USA\u00a0durchgef\u00fchrt. \u00a0S\u00e4uglinge, \u00a0die\u00a0im\u00a0Zeitraum\u00a0von\u00a0bis\u00a0zu\u00a028\u00a0Tagen\u00a0nach\u00a0\nder\u00a01.\u00a0RV\u2010Impfstoffdosis \u00a0hospitalisiert \u00a0werden,\u00a0sollten\u00a0bis\u00a0zum\u00a028.\u00a0postvakzinalen \u00a0Tag\u00a0unter\u00a0\nEinhaltung \u00a0der\u00a0\u00fcblichen\u00a0Standardhygienema\u00dfnahmen \u00a0zur\u00a0Verhinderung \u00a0einer\u00a0f\u00e4kal\u2010oralen\u00a0\nImpfvirus\u00fcbertragung \u00a0gepflegt\u00a0werden.\u00a0Das\u00a0gleiche\u00a0gilt\u00a0f\u00fcr\u00a0S\u00e4uglinge \u00a0bis\u00a0zum\u00a014.\u00a0postvakzinalen \u00a0Tag,\u00a0\ndie\u00a0innerhalb \u00a0von\u00a014\u00a0Tagen\u00a0nach\u00a0der\u00a02.\u00a0oder\u00a03.\u00a0RV\u2010Impfstoffdosis \u00a0station\u00e4r\u00a0aufgenommen \u00a0werden.\u00a0\nDaher\u00a0sollte\u00a0bei\u00a0der\u00a0station\u00e4ren \u00a0Aufnahme \u00a0von\u00a0allen\u00a0S\u00e4uglingen \u00a0bis\u00a0zum\u00a0Alter\u00a0von\u00a08\u00a0Monaten\u00a0(unter\u00a0\nBer\u00fccksichtigung \u00a0des\u00a0sp\u00e4testen \u00a0Impfalters) \u00a0der\u00a0RV\u2010Impfstatus \u00a0erhoben\u00a0werden,\u00a0um\u00a0die\u00a0ggf.\u00a0\nerforderlichen \u00a0Hygienema\u00dfnahmen \u00a0ohne\u00a0Verzug\u00a0einleiten\u00a0zu\u00a0k\u00f6nnen.\u00a0\n\u00a03\u00a0\n\u00a0Begr\u00fcndung \tder\tStellungnahme \tzur\tRotavirus \u2010Impfung \tvon\tFr\u00fch\u2010\tund\t\nNeugeborenen \tim\tstation\u00e4ren \tUmfeld\t\t\nHintergrund \tund\tFragestellung \t\nBei\u00a0den\u00a0in\u00a0Deutschland \u00a0zugelassenen \u00a0Rotavirus \u00a0(RV)\u2010Impfstoffen \u00a0(Rotarix\u00ae\u00a0und\u00a0RotaTeq\u00ae) \u00a0handelt\u00a0es\u00a0\nsich\u00a0um\u00a0orale\u00a0Lebendimpfstoffe. \u00a0Es\u00a0ist\u00a0m\u00f6glich,\u00a0dass\u00a0durch\u00a0die\u00a0Ausscheidung \u00a0von\u00a0Impfviren \u00a0im\u00a0Stuhl\u00a0\nnach\u00a0erfolgter\u00a0Impfung\u00a0eine\u00a0f\u00e4kal\u2010orale\u00a0\u00dcbertragung \u00a0(z.\u00a0B.\u00a0im\u00a0Rahmen\u00a0von\u00a0Windelwechsel) \u00a0auf\u00a0\nungesch\u00fctzte \u00a0Kontaktpersonen \u00a0im\u00a0Umfeld\u00a0stattfindet \u00a0und\u00a0dadurch\u00a0ein\u00a0theoretisches \u00a0\nErkrankungsrisiko \u00a0besteht\u00a0[1].\u00a0Wie\u00a0bei\u00a0der\u00a0oralen\u00a0Polio\u2010Vakzine\u00a0kann\u00a0die\u00a0Ausscheidung \u00a0von\u00a0\nattenuierten \u00a0Impfviren \u00a0jedoch\u00a0auch\u00a0als\u00a0Vorteil\u00a0gesehen\u00a0werden,\u00a0da\u00a0prim\u00e4r\u00a0ungeimpfte \u00a0\nKontaktpersonen \u00a0durch\u00a0eine,\u00a0in\u00a0der\u00a0Regel\u00a0asymptomatische, \u00a0Infektion\u00a0mit\u00a0Impfviren \u00a0einen\u00a0Schutz\u00a0vor\u00a0\neiner\u00a0RV\u2010Gastroenteritis \u00a0erwerben \u00a0k\u00f6nnen\u00a0[2].\u00a0\u00a0\n\u00a0Das\u00a0Zeitfenster \u00a0f\u00fcr\u00a0eine\u00a0\nRV\u2010Impfung\u00a0ist\u00a0begrenzt, \u00a0da\u00a0die\u00a0Impfserie \u00a0im\u00a0chronologischen \u00a0Alter\u00a0(im\u00a0\nUnterschied \u00a0zum\u00a0biologischen \u00a0Alter)\u00a0von\u00a06\u00a0bis\u00a012\u00a0Wochen\u00a0begonnen \u00a0werden\u00a0soll.\u00a0Sehr\u00a0kleine\u00a0und\u00a0\nunreife\u00a0Fr\u00fchgeborene \u00a0werden\u00a0im\u00a0Alter\u00a0von\u00a012\u00a0Wochen\u00a0(sp\u00e4testes \u00a0empfohlenes \u00a0Alter\u00a0f\u00fcr\u00a0die\u00a01.\u00a0\nImpfstoffdosis) \u00a0h\u00e4ufig\u00a0noch\u00a0station\u00e4r\u00a0versorgt.\u00a0Aus\u00a0neonatologischer \u00a0und\u00a0krankenhaushygienischer \u00a0\nPerspektive \u00a0bestehen \u00a0Vorbehalte \u00a0bei\u00a0dieser\u00a0Patientengruppe, \u00a0insbesondere \u00a0auf\u00a0neonatologischen \u00a0\nIntensivstationen, \u00a0noch\u00a0w\u00e4hrend\u00a0des\u00a0station\u00e4ren \u00a0Aufenthaltes \u00a0eine\u00a0RV\u2010Impfung\u00a0durchzuf\u00fchren. \u00a0\nDiese\u00a0betreffen \u00a0eine\u00a0m\u00f6gliche\u00a0Unreife\u00a0des\u00a0Immunsystems \u00a0von\u00a0Fr\u00fchgeborenen \u00a0oder\u00a0Komorbidit\u00e4ten, \u00a0\ndie\u00a0zu\u00a0einer\u00a0schlechteren \u00a0Vertr\u00e4glichkeit \u00a0des\u00a0RV\u2010Impfstoffes \u00a0f\u00fchren\u00a0k\u00f6nnten.\u00a0Weiterhin \u00a0existiert\u00a0\nUnsicherheit \u00a0bez\u00fcglich \u00a0des\u00a0krankenhaushygienischen \u00a0Managements \u00a0von\u00a0S\u00e4uglingen, \u00a0die\u00a0kurz\u00a0nach\u00a0\neiner\u00a0ambulanten \u00a0RV\u2010Impfung\u00a0hospitalisiert \u00a0werden\u00a0m\u00fcssen.\u00a0\u00a0\n\u00a0Die\u00a0Evidenz,\u00a0die\u00a0als\u00a0Grundlage \u00a0f\u00fcr\u00a0die\u00a0STIKO\u2010Empfehlung \u00a0zur\u00a0routinem\u00e4\u00dfigen \u00a0RV\u2010Impfung\u00a0von\u00a0\nS\u00e4uglingen \u00a0diente,\u00a0wurde\u00a0ausf\u00fchrlich \u00a0in\u00a0einem\u00a0Hintergrundpapier \u00a0aufgearbeitet \u00a0und\u00a0dargestellt \u00a0[3].\u00a0\nHier\u00a0sind\u00a0unter\u00a0anderem\u00a0auch\u00a0Details\u00a0zur\u00a0Rotavirus \u2010Epidemiologie \u00a0in\u00a0Deutschland \u00a0und\u00a0zur\u00a0\nWirksamkeit \u00a0und\u00a0Sicherheit \u00a0der\u00a0Rotavirus \u2010Impfung\n\u00a0zu\u00a0finden.\u00a0Der\u00a0vorliegende \u00a0Text\u00a0behandelt \u00a0daher\u00a0\ndie\u00a0speziellen \u00a0Aspekte\u00a0der\u00a0o.\u00a0g.\u00a0Fragestellung. \u00a0Die\u00a0hier\u00a0dargestellte \u00a0Evidenz\u00a0beruht\u00a0auf\u00a0der\u00a0Recherche \u00a0\nzum\u00a0erw\u00e4hnten \u00a0Hintergrundpapier \u00a0und\u00a0einer\u00a0aktuellen \u00a0orientierenden \u00a0Literaturrecherche. \u00a0\u00a0\nVirusmerkmale \t\nRV\u00a0sind\u00a0unbeh\u00fcllte, \u00a0doppelstr\u00e4ngige \u00a0RNA\u2010Viren\u00a0mit\u00a0segmentiertem \u00a0Genom,\u00a0die\u00a0zur\u00a0Familie\u00a0der\u00a0\nReoviridae \u00a0geh\u00f6ren.\u00a0RV\u00a0werden\u00a0f\u00e4kal\u2010oral\u00a0direkt\u00a0von\u00a0Mensch\u00a0zu\u00a0Mensch\u00a0oder\u00a0indirekt\u00a0\u00fcber\u00a0\nkontaminierte \u00a0Oberfl\u00e4chen \u00a0\u00fcbertragen. \u00a0Auch\u00a0aufgrund\u00a0der\u00a0hohen\u00a0Umweltstabilit\u00e4t \u00a0sind\u00a0sie\u00a0sehr\u00a0\ninfekti\u00f6s\u00a0und\u00a0verf\u00fcgen\u00a0\u00fcber\u00a0ein\u00a0ausgepr\u00e4gtes \u00a0Ausbruchspotenzial. \u00a0Mehr\u00a0als\u00a050%\u00a0aller\u00a0nosokomialen \u00a0\nGastroenteritiden \u00a0in\u00a0Kinderkliniken \u00a0sind\u00a0durch\u00a0RV\u00a0bedingt\u00a0[4,\u00a05].\u00a0\u00a0\nKrankheitsbild \tund\tEpidemiologie \t\nRV\u00a0sind\u00a0weltweit\u00a0die\u00a0h\u00e4ufigsten \u00a0Erreger\u00a0akuter\u00a0Gastroenteritiden \u00a0bei\u00a0<5\u2010J\u00e4hrigen.\u00a0Nach\u00a0einmalig\u00a0\ndurchgemachter \u00a0RV\u2010Infektion\u00a0besteht\u00a0keine\u00a0vollst\u00e4ndige \u00a0lebenslange \u00a0Immunit\u00e4t. \u00a0Mit\u00a0jeder\u00a0RV\u2010\nInfektion\u00a0nimmt\u00a0die\u00a0Schutzrate \u00a0vor\u00a0einer\u00a0weiteren\u00a0Infektion\u00a0zwar\u00a0zu\u00a0und\u00a0die\u00a0Schwere\u00a0der\u00a0Erkrankung \u00a0\nab,\u00a0aber\u00a0RV\u2010Reinfektionen \u00a0treten\u00a0lebenslang \u00a0auf\u00a0[6,\u00a07].\u00a0RV\u2010bedingte\u00a0Todesf\u00e4lle \u00a0sind\u00a0hierzulande \u00a0zwar\u00a0\nsehr\u00a0selten,\u00a0aber\u00a0der\u00a0Krankheitsverlauf \u00a0der\u00a0RVGE\u00a0ist\u00a0bei\u00a0S\u00e4uglingen \u00a0und\u00a0Kleinkindern \u00a0h\u00e4ufig\u00a0schwer\u00a0\nund\u00a0erfordert\u00a0nicht\u00a0selten\u00a0eine\u00a0station\u00e4re \u00a0Behandlung. \u00a0In\u00a0Deutschland \u00a0ist\u00a0die\u00a0nach\u00a0dem\u00a0\nInfektionsschutzgesetz \u00a0(IfSG)\u00a0erfasste\u00a0Hospitalisationsrate \u00a0bei\u00a0Kindern\u00a0<5\u00a0Jahren\u00a0mit\u00a0516\u00a0\nErkrankten/100.000 \u00a0Kinder\u00a0(<5\u00a0Jahre)\u00a0betr\u00e4chtlich \u00a0[8].\u00a0Da\u00a0nicht\u00a0alle\u00a0F\u00e4lle\u00a0labordiagnostisch \u00a0best\u00e4tigt\u00a04\u00a0\n\u00a0und\u00a0gemeldet \u00a0werden,\u00a0kann\u00a0sogar\u00a0von\u00a0einer\u00a0deutlich\u00a0h\u00f6heren\u00a0Inzidenz\u00a0ausgegangen \u00a0werden.\u00a0Das\u00a0\nRisiko\u00a0im\u00a0Krankenhaus \u00a0eine\u00a0RV\u2010Infektion\u00a0zu\u00a0bekommen \u00a0ist\u00a0hoch,\u00a0etwa\u00a07,5%\u00a0der\u00a0gemeldeten \u00a0\nhospitalisierten \u00a0Kinder\u00a0mit\u00a0RVGE\u00a0haben\u00a0die\u00a0Infektion\u00a0nosokomial \u00a0erworben. \u00a0Fr\u00fchgeborene, \u00a0die\u00a0an\u00a0\neiner\u00a0RVGE\u00a0erkranken, \u00a0haben\u00a0im\u00a01.\u00a0Lebensjahr \u00a0im\u00a0Unterschied \u00a0zu\u00a0reif\u00a0Geborenen \u00a0ein\u00a0erh\u00f6htes\u00a0Risiko\u00a0\nzu\u00a0dehydrieren \u00a0und\u00a0hospitalisiert \u00a0zu\u00a0werden\u00a0[9\u201012].\u00a0Das\u00a0klinische\u00a0Spektrum \u00a0der\u00a0RVGE\u00a0stellt\u00a0sich\u00a0bei\u00a0\nFr\u00fch\u2010\u00a0im\u00a0Vergleich \u00a0zu\u00a0Reifgeborenen \u00a0ebenfalls\u00a0unterschiedlich \u00a0dar:\u00a0Fr\u00fchgeborene \u00a0erkranken \u00a0im\u00a0\nDurchschnitt \u00a0schwerer\u00a0als\u00a0Reifgeborene \u00a0und\u00a0zeigen\u00a0h\u00e4ufiger\u00a0Symptome \u00a0wie\u00a0blutige\u00a0bzw.\u00a0schleimige \u00a0\nSt\u00fchle,\u00a0Schwierigkeiten \u00a0beim\u00a0F\u00fcttern,\u00a0Darmdilatationen \u00a0und\u00a0nekrotisierende \u00a0Enterokolitiden \u00a0[13\u201015].\u00a0\nImpfstoff/ \tVakzine\t\nIm\u00a0Juni\u00a02006\u00a0wurden\u00a0von\u00a0der\u00a0Europ\u00e4ische \u00a0Arzneimittel \u2010Agentur,\u00a0EMA\u00a0(European \u00a0Medicines \u00a0Agency),\u00a0\nzwei\u00a0RV\u2010Impfstoffe \u00a0zugelassen. \u00a0\u00a0\nRotarix\u00ae\u00a0(GlaxoSmithKline \u00a0Biologicals) \u00a0ist\u00a0ein\u00a0oraler,\u00a0monovalenter \u00a0Lebendimpfstoff, \u00a0der\u00a0einen\u00a0\nattenuierten \u00a0humanen \u00a0G1[P8]\u2010Virus\u2010Stamm\u00a0enth\u00e4lt.\u00a0Eine\u00a0Impfstoffdosis \u00a0enth\u00e4lt\u00a0106\u00a0ZKID 50\u00a0(Zell\u2010\nKultur\u00a0infekti\u00f6se \u00a0Dosis\u00a050%;\u00a0die\u00a0Virusdosis, \u00a0die\u00a0statistisch \u00a050%\u00a0von\u00a0inokulierten \u00a0Zellkulturen \u00a0im\u00a0\nMehrfachansatz \u00a0infiziert).\u00a0Das\u00a0Virus\u00a0vermehrt \u00a0sich\u00a0nach\u00a0der\u00a0oralen\u00a0Aufnahme \u00a0gut\u00a0in\u00a0der\u00a0Schleimhaut \u00a0\ndes\u00a0D\u00fcnndarms. \u00a0\u00a0\nRotaTeq\u00ae \u00a0(Sanofi\u00a0Pasteur\u00a0MSD)\u00a0ist\u00a0ein\u00a0oraler\u00a0Lebendimpfstoff, \u00a0der\u00a05\u00a0RV\u2010Reassortanten \u00a0aus\u00a0humanen \u00a0\nund\u00a0bovinen\u00a0Viren\u00a0enth\u00e4lt.\u00a0Davon\u00a0exprimieren \u00a04\u00a0Reassortanten \u00a0je\u00a0eines\u00a0der\u00a0\u00e4u\u00dferen\u00a0Kapsidproteine \u00a0\n(G1,\u00a0G2,\u00a0G3,\u00a0G4)\u00a0humaner\u00a0Viren\u00a0und\u00a0das\u00a0Bindungsprotein \u00a0des\u00a0bovinen\u00a0Virus.\u00a0Die\u00a05.\u00a0Reassortante \u00a0\nexprimiert \u00a0das\u00a0Bindungsprotein \u00a0(P1[8])\u00a0eines\u00a0humanen \u00a0Virus\u00a0und\u00a0das\u00a0\u00e4u\u00dfere\u00a0Kapsidprotein \u00a0(G6)\u00a0des\u00a0\nbovinen\u00a0Virus.\u00a0Die\u00a0fertige\u00a0Impfstoffdosis \u00a0erh\u00e4lt\u00a0f\u00fcr\u00a0jede\u00a0Reassortante \u00a0\u22652,0\u00a0x\u00a0106\u00a0infekti\u00f6se \u00a0Einheiten. \u00a0\nDas\u00a0Impfvirus \u00a0vermehrt \u00a0sich\u00a0weniger\u00a0gut\u00a0im\u00a0D\u00fcnndarm \u00a0und\u00a0daher\u00a0enth\u00e4lt\u00a0die\u00a0RotaTeq\u00ae \u2010\nImpfstoffdosis \u00a0ca.\u00a010\u2010mal\u00a0mehr\u00a0infekti\u00f6se \u00a0Viren\u00a0als\u00a0Rotarix\u00ae.\u00a0\u00a0\nDie\u00a0Impfviren \u00a0imitieren\u00a0eine\u00a0nat\u00fcrliche \u00a0RV\u2010Infektion, \u00a0vermehren \u00a0sich\u00a0im\u00a0Darm\u00a0der\u00a0geimpften \u00a0\nS\u00e4uglinge, \u00a0induzieren \u00a0eine\u00a0Immunit\u00e4t \u00a0und\u00a0bieten\u00a0somit\u00a0einen\u00a0Schutz\u00a0vor\u00a0Infektionen \u00a0mit\u00a0RV\u2010\nWildtypen \u00a0[16,\u00a017].\u00a0Der\u00a0Schutz\u00a0vor\u00a0einer\u00a0RV\u2010bedingten \u00a0Krankenhausaufnahme \u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0\nvon\u00a02\u00a0Jahren\u00a0nach\u00a0abgeschlossener \u00a0Impfung\u00a0betr\u00e4gt\u00a092%\u00a0(95%\u00a0KI:\u00a082\u201096)\u00a0und\u00a0der\u00a0Schutz\u00a0vor\u00a0einer\u00a0\nschweren \u00a0RVGE\u00a091%\u00a0(95%\u00a0KI:\u00a082\u201095)\u00a0[3].\u00a0Die\u00a0Rotavirus \u2010Impfung\u00a0reduziert\u00a0die\u00a0RV\u2010bedingte\u00a0\nKrankheitslast \u00a0deutlich\u00a0und\u00a0senkt\u00a0damit\u00a0auch\u00a0die\u00a0verbundenen \u00a0Behandlungskosten \u00a0im\u00a0\nGesundheitssystem \u00a0[18\u201020].\u00a0\u00a0\nEine\u00a0m\u00f6gliche\u00a0f\u00e4kal\u2010orale\u00a0\u00dcbertragung \u00a0von\u00a0Impfviren \u00a0von\u00a0geimpften \u00a0S\u00e4uglingen \u00a0auf\u00a0ungeimpfte \u00a0\nPersonen \u00a0(z.\u00a0B.\u00a0beim\u00a0Windelwechsel) \u00a0w\u00fcrde\u00a0zwar\u00a0einerseits \u00a0die\u00a0M\u00f6glichkeit \u00a0der\u00a0Verst\u00e4rkung \u00a0eines\u00a0\nHerdenschutzes \u00a0beinhalten, \u00a0aber\u00a0gleichzeitig \u00a0best\u00fcnde \u00a0das\u00a0theoretische \u00a0Risiko\u00a0einer\u00a0Vakzine\u2010\nbedingten \u00a0RVGE,\u00a0insbesondere \u00a0bei\u00a0immunsupprimierten \u00a0Patienten. \u00a05\u00a0\n\u00a0Die\u00a0RV\u2010Impfung\u00a0von\u00a0S\u00e4uglingen \u00a0mit\u00a0schwerem \u00a0kombiniertem \u00a0Immundefekt \u00a0(SCID)\u00a0ist\u00a0kontraindiziert. \u00a0\nNach\u00a0RV\u2010Impfung\u00a0von\u00a0S\u00e4uglingen \u00a0mit\u00a0SCID\u00a0ist\u00a0eine\u00a0langanhaltende \u00a0Impfvirusausscheidung \u00a0begleitet\u00a0\nvon\u00a0langwierigen \u00a0Durchf\u00e4llen \u00a0und\u00a0anderen\u00a0Symptomen \u00a0(Erbrechen, \u00a0Gedeihst\u00f6rung) \u00a0beschrieben \u00a0\nworden\u00a0[17,\u00a021,\u00a022].\u00a0Die\u00a0Datenlage \u00a0zur\u00a0Vertr\u00e4glichkeit \u00a0des\u00a0RV\u2010Impfstoffes \u00a0bei\u00a0S\u00e4uglingen \u00a0mit\u00a0weniger\u00a0\nschweren \u00a0Immundefekten \u00a0ist\u00a0limitiert.\u00a0Bei\u00a0dem\u00a0derzeit\u00a0noch\u00a0hohen\u00a0Risiko\u00a0an\u00a0einer\u00a0nat\u00fcrlichen \u00a0RV\u2010\nInfektion\u00a0zu\u00a0erkranken \u00a0\u00fcberwiegen \u00a0jedoch\u00a0die\u00a0Vorteile\u00a0der\u00a0RV\u2010Impfung\u00a0die\u00a0Risiken,\u00a0sodass\u00a0eine\u00a0RV\u2010\nImpfung\u00a0geboten\u00a0erscheint. \u00a0In\u00a0Zweifelsf\u00e4llen \u00a0sollte\u00a0ein\u00a0p\u00e4diatrischer \u00a0Immunologe \u00a0zu\u00a0Rate\u00a0gezogen\u00a0\nwerden\u00a0[23].\u00a0\nImpfalter, \tImpfzeitraum \tsowie\tVerabreichung \tan\tFr\u00fchgeborene \t\t\nDie\u00a0Impfserie \u00a0mit\u00a0Rotarix\u00ae\u00a0besteht\u00a0laut\u00a0den\u00a0Herstellerinformationen \u00a0[24],\u00a0die\u00a0von\u00a0der\u00a0EMA\u00a0im\u00a0EPAR\u00a0\n(European \u00a0public\u00a0assessment \u00a0reports)\u00a0ver\u00f6ffentlicht \u00a0wurden,\u00a0aus\u00a0zwei\u00a0Impfstoffdosen. \u00a0Die\u00a01.\u00a0\nImpfstoffdosis \u00a0kann\u00a0ab\u00a0dem\u00a0Alter\u00a0von\u00a06\u00a0Wochen\u00a0gegeben\u00a0werden.\u00a0Zwischen \u00a0den\u00a0einzelnen \u00a0\nImpfstoffdosen \u00a0ist\u00a0ein\u00a0Zeitabstand \u00a0von\u00a0mindestens \u00a04\u00a0Wochen\u00a0einzuhalten. \u00a0Die\u00a0Impfserie \u00a0sollte\u00a0\nvorzugsweise \u00a0vor\u00a0dem\u00a0Alter\u00a0von\u00a016\u00a0Wochen\u00a0verabreicht \u00a0werden,\u00a0muss\u00a0aber\u00a0auf\u00a0jeden\u00a0Fall\u00a0bis\u00a0zum\u00a0\nAlter\u00a0von\u00a024\u00a0Wochen\u00a0abgeschlossen \u00a0sein.\u00a0Rotarix\u00ae\u00a0kann\u00a0in\u00a0der\u00a0gleichen\u00a0Dosierung \u00a0an\u00a0Fr\u00fchgeborene, \u00a0\ndie\u00a0mit\u00a0einem\u00a0Gestationsalter \u00a0von\u00a0mindestens \u00a027\u00a0Wochen\u00a0geboren\u00a0wurden,\u00a0verabreicht \u00a0werden.\u00a0\nDie\u00a0Impfserie \u00a0von\u00a0RotaTeq\u00ae \u00a0besteht\u00a0laut\u00a0den\u00a0Herstellerinformationen \u00a0[25],\u00a0die\u00a0von\u00a0der\u00a0EMA\u00a0im\u00a0EPAR\u00a0\nver\u00f6ffentlicht \u00a0wurden,\u00a0aus\u00a03\u00a0Impfstoffdosen. \u00a0Die\u00a01.\u00a0Impfstoffdosis \u00a0kann\u00a0ab\u00a0Vollendung \u00a0der\u00a06.\u00a0\nLebenswoche, \u00a0sollte\u00a0jedoch\u00a0sp\u00e4testens \u00a0in\u00a0der\u00a012.\u00a0Lebenswoche \u00a0verabreicht \u00a0werden.\u00a0Ein\u00a0Abstand\u00a0von\u00a0\nmindestens \u00a04\u00a0Wochen\u00a0zwischen\u00a0den\u00a0einzelnen \u00a0Impfstoffdosen \u00a0sollte\u00a0eingehalten \u00a0werden.\u00a0Die\u00a0\nGrundimmunisierung \u00a0mit\u00a03\u00a0Impfstoffdosen \u00a0sollte\u00a0vorzugsweise \u00a0bis\u00a0zur\u00a0Vollendung \u00a0der\u00a020.\u00a0bzw.\u00a022.\u00a0\nLebenswoche \u00a0abgeschlossen \u00a0sein,\u00a0muss\u00a0aber\u00a0auf\u00a0jeden\u00a0Fall\u00a0bis\u00a0zur\u00a0Vollendung \u00a0der\u00a032.\u00a0Lebenswoche \u00a0\nabgeschlossen \u00a0werden.\u00a0RotaTeq\u00ae \u00a0kann\u00a0Fr\u00fchgeborenen, \u00a0die\u00a0mit\u00a0einem\u00a0Gestationsalter \u00a0von\u00a0\nmindestens \u00a025\u00a0Wochen\u00a0geboren\u00a0wurden,\u00a0verabreicht \u00a0werden.\u00a0Die\u00a01.\u00a0Impfstoffdosis \u00a0k\u00f6nnen\u00a0diese\u00a0\nS\u00e4uglinge \u00a0ebenfalls\u00a06\u00a0Wochen\u00a0nach\u00a0der\u00a0Geburt\u00a0erhalten.\u00a0\nSicherheit \tder\tImpfstoffe \tbei\tFr\u00fchgeborenen \t\nIn\u00a0einer\u00a0randomisierten \u00a0(2:1;\u00a0Vakzine\u00a0:\u00a0Placebo)\u00a0doppelblinden \u00a0klinischen \u00a0Phase\u00a0IIIb\u2010Zulassungsstudie, \u00a0\ndie\u00a0in\u00a0Europa\u00a0zwischen\u00a0Januar\u00a02007\u00a0und\u00a0M\u00e4rz\u00a02008\u00a0bei\u00a0Fr\u00fchgeborenen \u00a0mit\u00a0einem\u00a0Gestationsalter \u00a0\nzwischen\u00a027\u00a0und\u00a036\u00a0Wochen\u00a0durchgef\u00fchrt \u00a0wurde,\u00a0erhielten\u00a0670\u00a0Fr\u00fchgeborene \u00a0Rotarix\u00ae\u00a0und\u00a0339\u00a0\nFr\u00fchgeborene \u00a0Placebo\u00a0[26].\u00a0Auf\u00a0der\u00a0Basis\u00a0des\u00a0Gestationsalters \u00a0wurden\u00a0die\u00a0S\u00e4uglinge \u00a0in\u00a0zwei\u00a0Gruppen\u00a0\neingeteilt: \u00a020%\u00a0der\u00a0S\u00e4uglinge \u00a0geh\u00f6rten\u00a0zur\u00a0Gruppe\u00a01\u00a0mit\u00a0einem\u00a0Gestationsalter \u00a0von\u00a027\u00a0bis\u00a030\u00a0\nWochen\u00a0und\u00a080%\u00a0zur\u00a0Gruppe\u00a02\u00a0mit\u00a0einem\u00a0Gestationsalter \u00a0von\u00a031\u00a0bis\u00a036\u00a0Wochen.\u00a0Die\u00a01.\u00a0\nImpfstoffdosis \u00a0wurde\u00a0ab\u00a0dem\u00a0Alter\u00a0von\u00a06\u00a0Wochen\u00a0verabreicht. \u00a0Schwere\u00a0unerw\u00fcnschte \u00a0Ereignisse \u00a0\nwurden\u00a0in\u00a0gleicher\u00a0H\u00e4ufigkeit \u00a0in\u00a0beiden\u00a0Gruppen\u00a0beobachtet; \u00a0sie\u00a0traten\u00a0bei\u00a05,1%\u00a0(95%\u00a0KI:\u00a03,5\u20107,1)\u00a0der\u00a0\nRotarix\u00ae\u2010Gruppe\u00a0und\u00a0bei\u00a06,8%\u00a0(95%\u00a0KI:\u00a04,3\u201010,0)\u00a0der\u00a0Placebo\u2010Gruppe\u00a0auf\u00a0(p=0,266). \u00a0Insgesamt \u00a0traten\u00a0\n5\u00a0F\u00e4lle\u00a0von\u00a0RVGE\u00a0im\u00a0Beobachtungszeitraum \u00a0auf,\u00a03\u00a0F\u00e4lle\u00a0in\u00a0der\u00a0Rotarix\u00ae\u2010\u00a0und\u00a02\u00a0F\u00e4lle\u00a0in\u00a0der\u00a0Plazebo\u2010\nGruppe.\u00a0Die\u00a0Erkrankung \u00a0trat\u00a0in\u00a0der\u00a0Rotarix\u00ae\u2010Gruppe\u00a01\u00a0bis\u00a05\u00a0Tage\u00a0nach\u00a0der\u00a0Impfung\u00a0auf\u00a0(es\u00a0wurde\u00a0\nImpfvirus \u00a0nachgewiesen) \u00a0und\u00a0in\u00a0den\u00a0anderen\u00a02\u00a0F\u00e4llen\u00a03\u00a0bis\u00a04\u00a0Tage\u00a0nach\u00a0Verabreichung \u00a0des\u00a0Plazebo,\u00a0\njeweils\u00a0durch\u00a0Wildtyp\u2010Virus\u00a0verursacht. \u00a0Andere\u00a0unerw\u00fcnschte \u00a0Arzneimittelwirkungen \u00a0wurden\u00a0in\u00a0\nvergleichbarer \u00a0H\u00e4ufigkeit \u00a0sowohl\u00a0in\u00a0der\u00a0Rotarix\u00ae\u2010\u00a0als\u00a0auch\u00a0in\u00a0der\u00a0Placebo\u2010Gruppe\u00a0beobachtet. \u00a0Im\u00a0\nZeitraum\u00a0von\u00a031\u00a0Tagen\u00a0nach\u00a0der\u00a0Impfung\u00a0trat\u00a0eine\u00a0Durchfallsymptomatik \u00a0bei\u00a02,7\u00a0%\u00a0aus\u00a0der\u00a0Vakzine\u2010\nGruppe\u00a0und\u00a0bei\u00a02,9%\u00a0aus\u00a0der\u00a0Plazebo\u2010Gruppe\u00a0auf.\u00a0Es\u00a0wurden\u00a0keine\u00a0F\u00e4lle\u00a0von\u00a0Invagination \u00a0berichtet. \u00a0\nDiese\u00a0Ergebnisse \u00a0best\u00e4tigen \u00a0das\u00a0gute\u00a0Sicherheitsprofil \u00a0von\u00a0Rotarix\u00ae\u00a0aus\u00a0den\u00a0Zulassungsstudien \u00a0bei\u00a0\nReifgeborenen \u00a0[27\u201029].\u00a0\u00a06\u00a0\n\u00a0Im\u00a0Rahmen\u00a0der\u00a0geblindeten \u00a0Plazebo\u2010kontrollierten \u00a0randomisierten \u00a0(1:1)\u00a0REST\u2010Studie\u00a0wurde\u00a0\nRotaTeq\u00ae \u00a0bei\u00a0Fr\u00fchgeborenen \u00a0mit\u00a0einem\u00a0Gestationsalter \u00a0von\u00a025\u00a0bis\u00a036\u00a0Wochen\u00a0(Median:\u00a034\u00a0Wochen)\u00a0\nuntersucht \u00a0[30\u201032].\u00a0In\u00a0der\u00a0Studie\u00a0erhielten\u00a01.005\u00a0Fr\u00fchgeborene \u00a0RotaTeq\u00ae \u00a0und\u00a01.061\u00a0Fr\u00fchgeborene \u00a0\nPlacebo.\u00a0Unter\u00a0den\u00a0Fr\u00fchgeborenen \u00a0waren\u00a0166\u00a0fr\u00fchgeborene \u00a0S\u00e4uglinge \u00a0mit\u00a0einem\u00a0Gestationsalter \u00a0\n<32\u00a0Wochen\u00a0(Vakzine\u2010Gruppe:\u00a0n=74,\u00a0Plazebo\u2010Gruppe\u00a0n=92).\u00a0Die\u00a01.\u00a0Impfstoffdosis \u00a0wurde\u00a0fr\u00fchestens \u00a0\n6\u00a0Wochen\u00a0nach\u00a0der\u00a0Geburt\u00a0verabreicht. \u00a0Schwere\u00a0unerw\u00fcnschte \u00a0Arzneimittelwirkungen \u00a0wurden\u00a0in\u00a0\ngleicher\u00a0H\u00e4ufigkeit \u00a0in\u00a0beiden\u00a0Gruppen\u00a0beobachtet; \u00a0sie\u00a0traten\u00a0mit\u00a0einer\u00a0H\u00e4ufigkeit \u00a0von\u00a05,5%\u00a0in\u00a0der\u00a0\nRotaTeq\u00ae \u2010Gruppe\u00a0und\u00a0von\u00a05,8%\u00a0in\u00a0der\u00a0Placebo\u2010Gruppe\u00a0auf.\u00a0In\u00a0einer\u00a0Untergruppe \u00a0von\u00a0308\u00a0\nFr\u00fchgeborenen \u00a0(n=154\u00a0in\u00a0jeder\u00a0Gruppe)\u00a0wurden\u00a0unerw\u00fcnschte \u00a0Arzneimittelwirkungen \u00a0wie\u00a0Fieber,\u00a0\nDurchfall\u00a0und\u00a0Erbrechen \u00a0dokumentiert. \u00a0Die\u00a0H\u00e4ufigkeit \u00a0dieser\u00a0Ereignisse \u00a0war\u00a0in\u00a0beiden\u00a0Gruppen\u00a0\nvergleichbar. \u00a0Es\u00a0wurden\u00a0keine\u00a0F\u00e4lle\u00a0von\u00a0Invagination \u00a0berichtet. \u00a0Im\u00a0Zeitraum\u00a0von\u00a01\u00a0Woche\u00a0nach\u00a0jeder\u00a0\nder\u00a03\u00a0Impfungen \u00a0trat\u00a0eine\u00a0Durchfallsymptomatik \u00a0bei\u00a03,7\u00a0bis\u00a07,3%\u00a0der\u00a0Probanden \u00a0aus\u00a0der\u00a0Vakzine\u2010\nGruppe\u00a0und\u00a0bei\u00a03,9\u00a0bis\u00a07,3%\u00a0aus\u00a0der\u00a0Plazebo\u2010Gruppe\u00a0auf.\u00a0\u00a0\nImmunogenit\u00e4t \tund\tWirksamkeit \tder\tRV\u2010Vakzine\tbei\tFr\u00fchgeborenen \t\nIn\u00a0einer\u00a0Untergruppe \u00a0der\u00a0oben\u00a0beschriebenen \u00a0Studie\u00a0wurde\u00a0die\u00a0Immunogenit\u00e4t \u00a0von\u00a0Rotarix\u00ae\u00a0bei\u00a0147\u00a0\nFr\u00fchgeborenen \u00a0der\u00a0Rotarix\u00ae\u2010Gruppe\u00a0im\u00a0Vergleich \u00a0zu\u00a081\u00a0Fr\u00fchgeborenen \u00a0der\u00a0Plazebo\u2010Gruppe\u00a0\nuntersucht \u00a0[26].\u00a0Bei\u00a085,7%\u00a0(95%\u00a0KI:\u00a079,0\u201090,9)\u00a0der\u00a0Fr\u00fchgeborenen \u00a0waren\u00a0einen\u00a0Monat\u00a0nach\u00a0Gabe\u00a0der\u00a0\n2.\u00a0Impfstoffdosis \u00a0mittels\u00a0EIA\u00a0(Enzymimmunosassay) \u00a0Rotavirus \u2010IgA\u2010Antik\u00f6rperwerte \u00a0(im\u00a0Serum)\u00a0\u226520\u00a0\nU/ml\u00a0(EIA\u2010Grenzwert \u00a0f\u00fcr\u00a0Nachweis \u00a0von\u00a0Rotaviren) \u00a0nachweisbar. \u00a0Im\u00a0Vergleich \u00a0dazu\u00a0waren\u00a0es\u00a0nur\u00a016%\u00a0\n(95%\u00a0KI:\u00a08,8\u201025,9)\u00a0in\u00a0der\u00a0Plazebo\u2010Gruppe.\u00a0Die\u00a0klinische\u00a0Wirksamkeit \u00a0von\u00a0Rotarix\u00ae\u00a0bei\u00a0Fr\u00fchgeborenen \u00a0\nwurde\u00a0bislang\u00a0nicht\u00a0untersucht. \u00a0\u00a0\nZur\u00a0klinischen \u00a0Wirksamkeit \u00a0von\u00a0RotaTeq\u00ae \u00a0bei\u00a0Fr\u00fchgeborenen \u00a0liegen\u00a0Daten\u00a0aus\u00a0den\u00a0REST\u2010\nZulassungsstudien \u00a0vor.\u00a0Danach\u00a0reduzierte \u00a0die\u00a0Gabe\u00a0von\u00a0insgesamt \u00a03\u00a0Impfstoffdosen \u00a0des\u00a0F\u00fcnffach\u2010\nImpfstoffs \u00a0RotaTeq\u00ae \u00a0die\u00a0Rate\u00a0der\u00a0Krankenhauseinweisungen \u00a0und\u00a0Notfallbehandlungen \u00a0bei\u00a0\nFr\u00fchgeborenen \u00a0durch\u00a0RVGE\u00a0im\u00a0Vergleich \u00a0zur\u00a0Placebo\u2010Gruppe\u00a0um\u00a0100%\u00a0(95%\u00a0KI:\u00a082,2\u2010100).\u00a0Die\u00a0\nWirksamkeit \u00a0von\u00a0RotaTeq\u00ae \u00a0war\u00a0in\u00a0der\u00a0Untergruppe \u00a0der\u00a0Fr\u00fchgeborenen \u00a0und\u00a0bei\u00a0zum\u00a0Termin\u00a0\ngeborenen \u00a0S\u00e4uglingen \u00a0vergleichbar \u00a0[31,\u00a032].\u00a0\u00a0\nAusscheidung \tvon\tImpfviren \tbzw.\tneuen\tnicht\turspr\u00fcnglich \tim\tImpfstoff \tenthaltenen \t\nReassortanten \tund\tderen\t\u00dcbertragung \t\nGenerell\u00a0kann\u00a0gesagt\u00a0werden,\u00a0dass\u00a0bei\u00a0vielen\u00a0Studien\u00a0zum\u00a0Nachweis \u00a0der\u00a0Ausscheidung \u00a0von\u00a0Impfviren \u00a0\nein\u00a0EIA\u00a0zur\u00a0Anwendung \u00a0kam,\u00a0welcher\u00a0virale\u00a0Antigene\u00a0(Proteine) \u00a0nachweist \u00a0[30,\u00a033,\u00a034].\u00a0Der\u00a0EIA\u00a0hat\u00a0\nden\u00a0Vorteil,\u00a0dass\u00a0er\u00a0einfach\u00a0durchzuf\u00fchren \u00a0und\u00a0preiswert \u00a0ist.\u00a0Er\u00a0hat\u00a0jedoch\u00a0auch\u00a0deutliche \u00a0\nLimitationen, \u00a0denn\u00a0die\u00a0untere\u00a0Nachweisgrenze \u00a0liegt\u00a0bei\u00a0ca.\u00a0500.000\u00a0Viruspartikeln \u00a0pro\u00a0Testansatz. \u00a0In\u00a0\nStudien,\u00a0die\u00a0nur\u00a0den\u00a0EIA\u00a0zum\u00a0Nachweis \u00a0einsetzen, \u00a0wird\u00a0daher\u00a0die\u00a0tats\u00e4chliche \u00a0Virusausscheidung \u00a0\nuntersch\u00e4tzt. \u00a0Die\u00a0RT\u2010PCR\u00a0zum\u00a0Nachweis \u00a0viraler\u00a0RNA\u00a0ist\u00a0wesentlich \u00a0sensitiver \u00a0als\u00a0der\u00a0EIA\u00a0und\u00a0kann\u00a0\nzus\u00e4tzlich \u00a0noch\u00a0besser\u00a0zur\u00a0Quantifizierung \u00a0der\u00a0Virusmenge \u00a0benutzt\u00a0werden.\u00a0\nAusscheidung \tvon\tImpfviren \tin\tRotarix\u00ae \u2010\tund\tRotaTeq\u00ae \u2010Zulassungsstudien \t\nIm\u00a0Folgenden \u00a0wird\u00a0ein\u00a0\u00dcberblick \u00a0\u00fcber\u00a0die\u00a0bisher\u00a0ver\u00f6ffentlichten \u00a0Daten\u00a0zur\u00a0Ausscheidung \u00a0sowie\u00a0der\u00a0\n\u00dcbertragung \u00a0von\u00a0Impfviren \u00a0nach\u00a0Rotarix\u00ae\u2010\u00a0bzw.\u00a0RotaTeq\u00ae \u2010Impfung\u00a0gegeben.\u00a0Obwohl\u00a0die\u00a0\nInterpretation \u00a0der\u00a0Ergebnisse \u00a0aufgrund\u00a0anderer\u00a0Studiendesigns, \u00a0unterschiedlicher \u00a0geimpfter \u00a0\nPopulationen \u00a0sowie\u00a0aufgrund\u00a0verschiedener \u00a0Nachweisverfahren \u00a0limitiert\u00a0ist,\u00a0k\u00f6nnen\u00a0wichtige\u00a07\u00a0\n\u00a0Schlussfolgerungen \u00a0gezogen\u00a0werden.\u00a0Es\u00a0liegen\u00a0allerdings \u00a0nur\u00a0wenige\u00a0Daten\u00a0zur\u00a0Ausscheidung \u00a0von\u00a0\nImpfviren \u00a0bei\u00a0Fr\u00fchgeborenen \u00a0vor.\u00a0\u00a0\nIn\u00a0einer\u00a0\u00dcbersicht \u00a0von\u00a0Anderson \u00a0werden\u00a0die\u00a0Daten\u00a0zur\u00a0Impfvirusausscheidung \u00a0aus\u00a0den\u00a0\nZulassungsstudien \u00a0zu\u00a0Rotarix\u00ae\u00a0und\u00a0RotaTeq\u00ae \u00a0zusammengestellt \u00a0[1].\u00a0In\u00a0den\u00a0meisten\u00a0Rotarix\u00ae\u2010Studien\u00a0\nwurde\u00a0der\u00a0Antigen\u2010EIA\u00a0zum\u00a0Nachweis \u00a0der\u00a0Impfviren \u00a0eingesetzt. \u00a0Demnach \u00a0scheiden\u00a0etwa\u00a050%\u00a0\n(Spanne:\u00a035\u201080%)\u00a0der\u00a0geimpften \u00a0S\u00e4uglinge \u00a0nach\u00a0der\u00a01.\u00a0Impfstoffdosis \u00a0Virusantigen \u00a0aus,\u00a0wobei\u00a0das\u00a0\nMaximum \u00a0um\u00a0den\u00a07.\u00a0postvakzinalen \u00a0Tag\u00a0liegt.\u00a0Die\u00a0Ausscheidung \u00a0von\u00a0Impfviren \u00a0im\u00a0Stuhl\u00a0tritt\u00a0h\u00e4ufiger\u00a0\nnach\u00a0der\u00a01.\u00a0als\u00a0nach\u00a0der\u00a02.\u00a0Impfstoffdosis \u00a0auf.\u00a0Nach\u00a0der\u00a02.\u00a0Impfstoffdosis \u00a0betr\u00e4gt\u00a0die\u00a0Rate\u00a0nur\u00a0noch\u00a0\nzwischen\u00a011\u00a0und\u00a029%.\u00a0Eine\u00a0Studie,\u00a0die\u00a0die\u00a0Ausscheidung \u00a0\u00fcber\u00a0die\u00a0Zeit\u00a0nach\u00a0beiden\u00a0Impfstoffdosen \u00a0\ngenauer\u00a0untersuchte, \u00a0zeigte,\u00a0dass\u00a076\u201080%\u00a0der\u00a0S\u00e4uglinge \u00a0am\u00a0Tag\u00a07\u00a0und\u00a018\u201024%\u00a0am\u00a0Tag\u00a030\u00a0(Tag\u00a0der\u00a02.\u00a0\nImpfung)\u00a0Impfvirus \u00a0ausschieden. \u00a0Nach\u00a0der\u00a02.\u00a0Impfstoffdosis \u00a0schieden\u00a018\u201029%\u00a0Impfvirus \u00a0am\u00a0Tag\u00a07\u00a0und\u00a0\n11\u201016%\u00a0am\u00a0Tag\u00a015\u00a0aus.\u00a0Die\u00a0Ausscheidung \u00a0war\u00a0generell\u00a0nicht\u00a0mit\u00a0einer\u00a0Zunahme \u00a0der\u00a0\ngastroenteritischen \u00a0Symptomatik \u00a0assoziiert. \u00a0Die\u00a0genaue\u00a0Dauer\u00a0der\u00a0Ausscheidung \u00a0ist\u00a0nicht\u00a0bestimmt \u00a0\nworden.\u00a0Die\u00a0Ausscheidungsrate \u00a0nach\u00a0einer\u00a0nat\u00fcrlichen \u00a0RV\u2010Infektion\u00a0ist\u00a0etwa\u00a03\u2010mal\u00a0so\u00a0hoch,\u00a0wie\u00a0die\u00a0\nAusscheidungsrate \u00a0nach\u00a0einer\u00a0Rotarix\u00ae\u2010Impfung\u00a0[35].\u00a0Die\u00a0\u00dcbertragung \u00a0von\u00a0Impfviren \u00a0wurde\u00a0in\u00a0den\u00a0\nmeisten\u00a0Studien\u00a0untersucht; \u00a0es\u00a0konnten\u00a0insgesamt \u00a05\u00a0F\u00e4lle\u00a0einer\u00a0\u00dcbertragung \u00a0von\u00a0Impfviren \u00a0in\u00a02\u00a0\nStudien\u00a0beobachtet \u00a0werden,\u00a0wovon\u00a0bei\u00a04\u00a0F\u00e4llen\u00a0in\u00a0der\u00a0Folge\u00a0eine\u00a0IgA\u2010Antwort\u00a0bei\u00a0den\u00a0infizierten \u00a0\nPersonen \u00a0resultierte \u00a0[36,\u00a037].\u00a0In\u00a0den\u00a0beiden\u00a0Studien\u00a0trat\u00a0eine\u00a0\u00dcbertragung \u00a0bei\u00a02/78\u00a0F\u00e4llen\u00a0(3%)\u00a0und\u00a0\nbei\u00a03/50\u00a0F\u00e4llen\u00a0(6%)\u00a0auf.\u00a0Dabei\u00a0handelte\u00a0es\u00a0sich\u00a0in\u00a0allen\u00a0F\u00e4llen\u00a0um\u00a0immunkompetente \u00a0S\u00e4uglinge \u00a0und\u00a0\nbei\u00a0keinem\u00a0Kind\u00a0trat\u00a0eine\u00a0Durchfall\u2010Symptomatik \u00a0auf.\u00a0\nIn\u00a0den\u00a0RotaTeq\u00ae \u2010Zulassungsstudien \u00a0wurde\u00a0die\u00a0Ausscheidung \u00a0von\u00a0infekti\u00f6sen \u00a0Impfviren \u00a0meist\u00a0mittels\u00a0\nMA104\u2010Zellkultur \u00a0bestimmt \u00a0[1].\u00a0Sie\u00a0trat\u00a0bei\u00a00\u00a0bis\u00a013%\u00a0der\u00a0Geimpften \u00a0nach\u00a0der\u00a01.\u00a0Impfstoffdosis, \u00a0bei\u00a0\n0\u20107%\u00a0nach\u00a0der\u00a02.\u00a0Impfstoffdosis \u00a0und\u00a0bei\u00a00\u00a0bis\u00a03%\u00a0nach\u00a0der\u00a03.\u00a0Impfstoffdosis \u00a0auf.\u00a0Die\u00a0Dauer\u00a0der\u00a0\nAusscheidung \u00a0betrug\u00a01\u00a0bis\u00a015\u00a0Tage\u00a0und\u00a0das\u00a0Maximum \u00a0wurde\u00a0zwischen\u00a0dem\u00a06.\u00a0bis\u00a08.\u00a0Tag\u00a0erreicht.\u00a0In\u00a0\nkeiner\u00a0Studie,\u00a0die\u00a0die\u00a0\u00dcbertragung \u00a0von\u00a0RotaTeq\u00ae \u2010Impfviren \u00a0untersuchte, \u00a0konnte\u00a0eine\u00a0solche\u00a0\nnachgewiesen \u00a0werden .\u00a0Dies\u00a0l\u00e4sst\u00a0sich\u00a0auch\u00a0dadurch\u00a0erkl\u00e4ren,\u00a0dass\u00a0die\u00a0Virusausscheidung \u00a0geringer\u00a0ist\u00a0\n[1].\u00a0Die\u00a0erforderliche \u00a0Infektionsdosis \u00a0von\u00a0RotaTeq\u00ae \u00a0ist\u00a0nicht\u00a0genau\u00a0bekannt,\u00a0aber\u00a0auf\u00a0Grundlage \u00a0der\u00a0\nverf\u00fcgbaren \u00a0Daten\u00a0nimmt\u00a0man\u00a0einen\u00a0Wert\u00a0in\u00a0der\u00a0Gr\u00f6\u00dfenordnung \u00a0von\u00a010\u2077\u00a0PFU/ml\u00a0(PFU =\u00a0Plaque\u2010\nbildenden \u00a0Einheiten )\u00a0an.\u00a0Im\u00a0Stuhl\u00a0von\u00a0Geimpften \u00a0wurde\u00a0RotaTeq\u00ae \u00a0in\u00a0einer\u00a0Konzentration \u00a0von\u00a0bis\u00a0zu\u00a0\n104,9\u00a0PFU/ml\u00a0ausgeschieden. \u00a0Das\u00a0bedeutet, \u00a0dass\u00a0eine\u00a0orale\u00a0Aufnahme \u00a0von\u00a010\u00a0bis\u00a0100\u00a0ml\u00a0Stuhl\u00a0\nnotwendig \u00a0w\u00e4re,\u00a0um\u00a0die\u00a0erforderliche \u00a0Infektionsdosis \u00a0von\u00a0RotaTeq\u00ae \u00a0zu\u00a0erreichen. \u00a0\nEs\u00a0wurde\u00a0auch\u00a0die\u00a0Ausscheidung \u00a0von\u00a0Impfviren \u00a0bei\u00a0Fr\u00fchgeborenen \u00a0untersucht, \u00a0allerdings \u00a0bei\u00a0einer\u00a0\nsehr\u00a0kleinen\u00a0Zahl\u00a0(n=7).\u00a0Es\u00a0wurde\u00a0im\u00a0Zeitraum\u00a0von\u00a04\u00a0bis\u00a06\u00a0Tagen\u00a0nach\u00a0keiner\u00a0der\u00a03\u00a0Impfstoffdosen \u00a0\nImpfvirus \u00a0im\u00a0Stuhl\u00a0der\u00a0Geimpften \u00a0nachgewiesen \u00a0[32].\u00a0\u00a0\nAusscheidung \tvon\tImpfviren \tin\tPost\u2010Marketing \u2010Studien\t\nIn\u00a0einer\u00a0Postmarketing \u2010Studie\u00a0wurde\u00a0die\u00a0Ausscheidung \u00a0von\u00a0RotaTeq\u00ae \u2010Impfviren \u00a0bei\u00a0S\u00e4uglingen \u00a0im\u00a0\nZeitraum\u00a0vom\u00a01\u20109\u00a0Tagen\u00a0nach\u00a0Gabe\u00a0der\u00a01.\u00a0Impfstoffdosis \u00a0untersucht. \u00a0Im\u00a0Stuhl\u00a0von\u00a022\u00a0(21,4%)\u00a0der\u00a0103\u00a0\nuntersuchten \u00a0Kinder\u00a0konnte\u00a0zumindest \u00a0an\u00a0einem\u00a0der\u00a0Tage\u00a0Impfvirus \u00a0mittels\u00a0EIA\u00a0nachgewiesen \u00a0\nwerden.\u00a0Das\u00a0Maximum \u00a0der\u00a0Virusausscheidung \u00a0lag\u00a0zwischen\u00a0dem\u00a06.\u00a0bis\u00a08.\u00a0Tag\u00a0nach\u00a0Impfung\u00a0[33].\u00a0\u00a0\nZus\u00e4tzlich \u00a0wurde\u00a0die\u00a0Ausscheidung \u00a0von\u00a0Impfviren \u00a0nach\u00a0RotaTeq\u00ae \u2010Impfung\u00a0bei\u00a0Fr\u00fchgeborenen \u00a0in\u00a0\neiner\u00a0Postmarketing \u2010Studie\u00a0untersucht. \u00a0Es\u00a0wurden\u00a015\u00a0Fr\u00fchgeborene \u00a0mit\u00a0einem\u00a0Gestationsalter \u00a0von\u00a0\n26\u00a0bis\u00a034\u00a0(Mittel:\u00a029\u00a0Wochen)\u00a0Wochen\u00a0im\u00a0Alter\u00a0von\u00a06\u00a0bis\u00a014\u00a0Wochen\u00a0mit\u00a0RotaTeq\u00ae \u00a0geimpft.\u00a0Bei\u00a08\u00a0von\u00a08\u00a0\n\u00a015\u00a0(53%)\u00a0geimpften \u00a0Kindern\u00a0konnte\u00a0mittels\u00a0EIA\u00a0und\u00a0bei\u00a013/15\u00a0(86,7%)\u00a0mittels\u00a0RT\u2010PCR\u00a0mindestens \u00a0\neinmal\u00a0im\u00a0Zeitraum\u00a0von\u00a02\u00a0Wochen\u00a0nach\u00a0der\u00a0Impfung\u00a0RV\u00a0nachgewiesen \u00a0werden.\u00a0Keiner\u00a0der\u00a053\u00a0\nHaushaltskontakte \u00a0(Alter,\u00a0Impfstatus \u00a0und\u00a0Geschlecht \u00a0nicht\u00a0angegeben) \u00a0berichtete \u00a0im\u00a0Zeitraum\u00a0von\u00a04\u00a0\nWochen\u00a0nach\u00a0der\u00a0Impfung\u00a0des\u00a0S\u00e4uglings \u00a0\u00fcber\u00a0Symptome \u00a0einer\u00a0RVGE\u00a0[38].\u00a0\u00a0\nIn\u00a0einer\u00a0Postmarketing \u2010Studie\u00a0von\u00a0Hsieh\u00a0wurde\u00a0von\u00a0M\u00e4rz\u00a02010\u00a0bis\u00a0Juni\u00a02011\u00a0in\u00a0zwei\u00a0Gruppen\u00a0von\u00a0\ngesunden \u00a0S\u00e4uglingen, \u00a0die\u00a0einen\u00a0vollst\u00e4ndigen \u00a0RotaTeq\u00ae \u2010\u00a0bzw.\u00a0Rotarix\u00ae\u2010Impfzyklus \u00a0erhalten\u00a0hatten,\u00a0\ndie\u00a0Ausscheidung \u00a0von\u00a0Impfviren \u00a0im\u00a0Zeitraum\u00a0von\u00a0einem\u00a0Monat\u00a0nach\u00a0der\u00a0Impfung\u00a0mittels\u00a0EIA\u00a0oder\u00a0\nRT\u2010PCR\u00a0untersucht \u00a0[39].\u00a0Es\u00a0wurden\u00a087\u00a0Kinder\u00a0rekrutiert. \u00a0Nach\u00a0der\u00a01.\u00a0Impfstoffdosis \u00a0trat\u00a0die\u00a0maximale \u00a0\nVirusausscheidung \u00a0im\u00a0Zeitraum\u00a0von\u00a04\u00a0bis\u00a07\u00a0Tagen\u00a0nach\u00a0der\u00a0Impfung\u00a0auf.\u00a0Der\u00a0Nachweis \u00a0von\u00a0Impfvirus \u00a0\ngelang\u00a0in\u00a0beiden\u00a0Gruppen\u00a0zwischen\u00a0dem\u00a01.\u00a0und\u00a0dem\u00a025.\u00a0bis\u00a028.\u00a0Tag\u00a0nach\u00a0der\u00a01.\u00a0Impfung\u00a0(aufgrund \u00a0\nder\u00a0n\u00e4chsten\u00a0Impfung\u00a0erfolgte\u00a0keine\u00a0weitere\u00a0Stuhluntersuchung), \u00a0im\u00a0Zeitraum\u00a0von\u00a015\u00a0Tagen\u00a0nach\u00a0der\u00a0\n2.\u00a0Impfung\u00a0mit\u00a0Rotarix\u00ae\u00a0und\u00a0einem\u00a0Zeitraum\u00a0von\u00a014\u00a0Tagen\u00a0nach\u00a0der\u00a02.\u00a0und\u00a03.\u00a0Impfung\u00a0mit\u00a0RotaTeq\u00ae. \u00a0\nDas\u00a0Auftreten \u00a0von\u00a0Impfvirus \u2010Ausscheidung \u00a0war\u00a0in\u00a0den\u00a0beiden\u00a0Gruppen\u00a0nach\u00a0den\u00a0ersten\u00a0beiden\u00a0\nImpfungen \u00a0nicht\u00a0signifikant \u00a0unterschiedlich. \u00a0In\u00a0beiden\u00a0Gruppen\u00a0wurde\u00a0bei\u00a086\u00a0bis\u00a090%\u00a0der\u00a0Geimpften \u00a0\nmittels\u00a0RT\u2010PCR\u00a0und\u00a0bei\u00a020\u00a0bis\u00a030%\u00a0mittels\u00a0EIA\u00a0im\u00a0Zeitraum\u00a0von\u00a04\u00a0bis\u00a07\u00a0Tagen\u00a0nach\u00a0der\u00a01.\u00a0Impfung\u00a0\nVakzine\u2010Virus\u00a0nachgewiesen. \u00a0Die\u00a0Ausscheidungsrate \u00a0nach\u00a0der\u00a01.\u00a0Impfstoffdosis \u00a0war\u00a0f\u00fcr\u00a0beide\u00a0\nImpfstoffe \u00a0signifikant \u00a0h\u00f6her\u00a0als\u00a0nach\u00a0der\u00a0der\u00a02.\u00a0Impfstoffdosis \u00a0(p<0,001). \u00a0F\u00fcr\u00a0RotaTeq\u00ae \u00a0war\u00a0die\u00a0\nAusscheidungsrate \u00a0zwischen\u00a0der2.\u00a0und\u00a03.\u00a0Impfstoffdosis \u00a0nicht\u00a0signifikant \u00a0unterschiedlich \u00a0(p=0,38).\u00a0\nSignifikante \u00a0Unterschiede \u00a0zeigten\u00a0sich\u00a0allerdings \u00a0hinsichtlich \u00a0der\u00a0Virusmenge. \u00a0F\u00fcr\u00a0Rotarix\u00ae\u00a0war\u00a0die\u00a0\nVirusmenge \u00a0sowohl\u00a0nach\u00a0der\u00a01.\u00a0Impfstoffdosis \u00a0(p=0,001) \u00a0als\u00a0auch\u00a0nach\u00a0der\u00a02.\u00a0Impfstoffdosis \u00a0\n(p=0,039) \u00a0signifikant \u00a0h\u00f6her\u00a0als\u00a0nach\u00a0RotaTeq\u00ae \u2010Impfung.\u00a0Mittels\u00a0RT\u2010PCR\u00a0wurde\u00a0nach\u00a0der\u00a01.\u00a0\nImpfstoffdosis \u00a0eine\u00a0h\u00f6here\u00a0Ausscheidungsrate \u00a0und\u00a0eine\u00a0l\u00e4ngere\u00a0Ausscheidungsdauer \u00a0nachgewiesen. \u00a0\u00a0\n\u00a0\nAbb.\u00a01:\u00a0aus\u00a0der\u00a0Publikation \u00a0von\u00a0Y.\u00a0C.\u00a0Hsieh:\u00a0Comparison \u00a0of\u00a0virus\u00a0shedding\u00a0after\u00a0live\u00a0attenuated \u00a0and\u00a0\npentavalent \u00a0reassortant \u00a0rotavirus\u00a0vaccine\u00a0[39]:\u00a0Durchschnittliche \u00a0Konzentration \u00a0der\u00a0viralen\u00a0\nAusscheidung \u00a0bei\u00a0S\u00e4uglingen \u00a0nach\u00a0Rotarix\u00ae\u00a0(RV2)\u2010\u00a0und\u00a0RotaTeq\u00ae \u00a0(RV5)\u2010Gabe,\u00a0sofern\u00a0Impfviren \u00a0\nausgeschieden \u00a0wurden.\u00a0Die\u00a0Ausscheidung \u00a0wurde\u00a0mittels\u00a0RT\u2010PCR\u00a0nach\u00a0jeder\u00a0Impfstoffdosis \u00a0bestimmt. \u00a0\nDie\u00a03\u00a0Rechtecke \u00a0zeigen\u00a0Abschnitte, \u00a0in\u00a0denen\u00a0<15\u00a0Proben\u00a0pro\u00a0Datenpunkt \u00a0analysiert \u00a0werden\u00a0konnten.\u00a0\nDie\u00a0horizontale \u00a0unterbrochene \u00a0Linie\u00a0zeigt\u00a0die\u00a0Nachweisgrenze \u00a0der\u00a0PCR\u00a0an.\u00a0\n9\u00a0\n\u00a0\u00dcbertragung \tvon\tImpfviren \tauf\tKontaktpersonen \t\nIn\u00a0einer\u00a0prospektiven \u00a0randomisierten \u00a0doppelblinden \u00a0Plazebo\u2010kontrollierten \u00a0Studie\u00a0in\u00a0der\u00a0\nDominikanischen \u00a0Republik\u00a0(2007\u20102008)\u00a0wurde\u00a0erstmals\u00a0neben\u00a0der\u00a0Ausscheidung \u00a0auch\u00a0die\u00a0horizontale \u00a0\n\u00dcbertragung \u00a0von\u00a0Impfvirus \u00a0von\u00a0geimpften \u00a0auf\u00a0ungeimpfte \u00a0S\u00e4uglinge \u00a0bei\u00a0Zwillingen \u00a0im\u00a0selben\u00a0\nHaushalt\u00a0untersucht \u00a0[40].\u00a0Es\u00a0wurden\u00a0100\u00a0Zwillingspaare \u00a0gesunder \u00a06\u00a0bis\u00a014\u00a0Wochen\u00a0alter\u00a0Kinder\u00a0\n(Gestationsalter \u00a0\u226532\u00a0Wochen)\u00a0eingeschlossen. \u00a0Ein\u00a0Zwilling\u00a0erhielt\u00a0Rotarix\u00ae\u00a0und\u00a0der\u00a0andere\u00a0Plazebo.\u00a0\n\u00dcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a06\u00a0Wochen\u00a0wurden\u00a03\u2010mal\u00a0w\u00f6chentlich \u00a0Stuhlproben \u00a0mittels\u00a0EIA\u00a0untersucht. \u00a0\nDer\u00a0\u00fcberwiegende \u00a0Anteil\u00a0der\u00a0RV\u2010Antigen\u2010Ausscheidung \u00a0wurde\u00a0nach\u00a0Gabe\u00a0der\u00a01.\u00a0Impfstoffdosis \u00a0\nbeobachtet. \u00a0Das\u00a0Ausscheidungsmaximum \u00a0wurde\u00a0am\u00a06.\u00a0Tag\u00a0nach\u00a0der\u00a01.\u00a0Impfung\u00a0(50%\u00a0der\u00a0S\u00e4uglinge) \u00a0\nund\u00a0am\u00a08.\u00a0Tag\u00a0nach\u00a0der\u00a02.\u00a0Impfung\u00a0(18,9%)\u00a0gemessen. \u00a0Eine\u00a0Impfvirus \u2010\u00dcbertragung \u00a0wurde\u00a0auf\u00a015\u00a0von\u00a0\n80\u00a0Zwillingen \u00a0beobachtet, \u00a0die\u00a0Plazebo\u00a0erhalten\u00a0hatten\u00a0(18,8%;\u00a095%\u00a0KI:\u00a010,9\u201029,0).\u00a0In\u00a05\u00a0F\u00e4llen\u00a0war\u00a0die\u00a0\n\u00dcbertragung \u00a0jedoch\u00a0fraglich,\u00a0da\u00a0Impfvirus \u00a0im\u00a0Stuhl\u00a0bereits\u00a0zu\u00a0einem\u00a0Zeitpunkt \u00a0nachgewiesen \u00a0worden\u00a0\nwar,\u00a0als\u00a0im\u00a0Stuhl\u00a0des\u00a0geimpften \u00a0Zwillings\u00a0noch\u00a0keine\u00a0Ausscheidung \u00a0nachgewiesen \u00a0werden\u00a0konnte.\u00a0Ob\u00a0\ndies\u00a0durch\u00a0den\u00a0wenig\u00a0empfindlichen \u00a0EIA,\u00a0eine\u00a0Kreuzkontamination \u00a0der\u00a0Stuhlproben \u00a0oder\u00a0eine\u00a0nur\u00a0\nkurz\u00a0dauernde \u00a0Ausscheidung \u00a0im\u00a0geimpften \u00a0S\u00e4ugling\u00a0erkl\u00e4rt\u00a0werden\u00a0k\u00f6nnte,\u00a0bleibt\u00a0unklar.\u00a0Von\u00a0den\u00a015\u00a0\nZwillingen \u00a0aus\u00a0der\u00a0Plazebo\u2010Gruppe\u00a0mit\u00a0nachgewiesener \u00a0Impfvirus\u00fcbertragung \u00a0zeigten\u00a04\u00a0eine\u00a0Anti\u2010RV\u2010\nSerokonversion, \u00a0f\u00fcr\u00a0die\u00a0urs\u00e4chlich \u00a0die\u00a0Impfvirus \u2010\u00dcbertragung \u00a0verantwortlich \u00a0gemacht\u00a0werden\u00a0\nkonnte.\u00a0Bei\u00a03\u00a0von\u00a015\u00a0\u00dcbertragungsf\u00e4llen \u00a0konnte\u00a0infekti\u00f6ses \u00a0Impfvirus \u00a0durch\u00a0Vermehrung \u00a0in\u00a0der\u00a0\nMA104\u2010Zellkultur \u00a0nachgewiesen \u00a0werden.\u00a0Die\u00a0Ausscheidungsdauer \u00a0betrug\u00a0bei\u00a0Kindern,\u00a0die\u00a0Rotarix\u00ae\u00a0\nerhalten\u00a0hatten,\u00a0im\u00a0Median\u00a010\u00a0Tage\u00a0und\u00a0bei\u00a0den\u00a0Kindern\u00a0nach\u00a0Impfvirus \u2010\u00dcbertragung \u00a0im\u00a0Median\u00a04\u00a0\nTage.\u00a0Bei\u00a0keinem\u00a0der\u00a015\u00a0Zwillinge\u00a0mit\u00a0nachgewiesener \u00a0Impfvirus \u2010\u00dcbertragung \u00a0trat\u00a0in\u00a0der\u00a0Folge\u00a0eine\u00a0\nGastroenteritis \u2010Symptomatik \u00a0auf.\u00a0\u00a0\nSymptomatische \tRV\u2010Erkrankungen \tnach\t\u00dcbertragung \tvon\tImpfviren \t\nEs\u00a0gibt\u00a0einen\u00a0Fallbericht \u00a0einer\u00a0\u00dcbertragung \u00a0eines\u00a0RotaTeq\u00ae \u2010verwandten \u00a0Impfvirus \u00a0(G1P[8])\u00a0von\u00a0\neinem\u00a0gesunden, \u00a0immunkompetenten \u00a0Geschwisterkind \u00a0auf\u00a0ein\u00a0\u00e4lteres\u00a0gesundes, \u00a0\nimmunkompetentes \u00a0Geschwisterkind, \u00a0das\u00a0in\u00a0der\u00a0Folge\u00a0an\u00a0einer\u00a0symptomatischen \u00a0RVGE\u00a0erkrankte \u00a0\nund\u00a0in\u00a0einer\u00a0Notaufnahme \u00a0behandelt \u00a0werden\u00a0musste\u00a0[41].\u00a0Eine\u00a0RV\u2010Wildvirusinfektion \u00a0wurde\u00a0nicht\u00a0\nnachgewiesen. \u00a0Es\u00a0wird\u00a0vermutet, \u00a0dass\u00a0ein\u00a0Reassortment \u00a0zwischen\u00a0den\u00a0Genotypen \u00a0G1P[5]\u00a0und\u00a0G6P[8]\u00a0\nim\u00a0Impfstoff \u00a0bei\u00a0der\u00a0Replikation \u00a0im\u00a0Darm\u00a0des\u00a0geimpften \u00a0S\u00e4uglings \u00a0oder\u00a0im\u00a0Geschwisterkind \u00a0\nstattgefunden \u00a0hat.\u00a0M\u00f6glicherweise \u00a0hat\u00a0diese\u00a0Reassortante \u00a0eine\u00a0h\u00f6here\u00a0Virulenz\u00a0als\u00a0das\u00a0eigentliche \u00a0\nImpfvirus. \u00a0Diese\u00a0Beobachtung \u00a0wurde\u00a0im\u00a0Rahmen\u00a0einer\u00a0aktiven\u00a0Surveillance \u00a0gemacht, \u00a0die\u00a0>141.000 \u00a0\nKinder\u00a0im\u00a0Alter\u00a0von\u00a0<5\u00a0Jahren\u00a0umfasste. \u00a0Dieser\u00a0Einzelnachweis \u00a0l\u00e4sst\u00a0vermuten, \u00a0dass\u00a0es\u00a0sich\u00a0um\u00a0kein\u00a0\nh\u00e4ufig\u00a0auftretendes \u00a0Ereignis\u00a0handelt.\u00a0\nBoom\u00a0et\u00a0al.\u00a0berichten \u00a0\u00fcber\u00a05\u00a0F\u00e4lle,\u00a0die\u00a0im\u00a0Rahmen\u00a0einer\u00a0aktiven\u00a0Surveillance \u00a0von\u00a0akuter\u00a0\nGastroenteritis \u00a0(AGE)\u00a0bei\u00a0<5\u2010j\u00e4hrigen\u00a0Kindern\u00a0an\u00a0einem\u00a0Krankenhaus \u00a0in\u00a0Texas\u00a0identifiziert \u00a0wurden\u00a0\nund\u00a0in\u00a0deren\u00a0Stuhl\u00a0ein\u00a0Impfvirus \u00a0bzw.\u00a0eine\u00a0urspr\u00fcnglich \u00a0nicht\u00a0im\u00a0Impfstoff \u00a0enthaltene \u00a0Reassortante \u00a0\nnachgewiesen \u00a0wurde\u00a0[42].\u00a0Von\u00a0den\u00a04\u00a0Kindern\u00a0mit\u00a0Nachweis \u00a0von\u00a0RotaTeq\u00ae \u2010Impfvirus \u00a0bzw.\u00a0RotaTeq\u00ae \u2010\nReassortante \u00a0hatten\u00a03\u00a0Kinder\u00a0kurz\u00a0vor\u00a0Erkrankungsbeginn \u00a0die\u00a01.\u00a0RotaTeq\u00ae \u2010Impfung\u00a0erhalten\u00a0und\u00a0bei\u00a0\neinem\u00a0Kind\u00a0hatte\u00a0das\u00a0Geschwisterkind \u00a0eine\u00a0RotaTeq\u00ae \u2010Impfung\u00a0erhalten.\u00a0Bei\u00a0dem\u00a05.\u00a0ungeimpften \u00a0\nKind\u00a0wurde\u00a0Rotarix\u00ae\u2010Impfvirus \u00a0nachgewiesen, \u00a0wobei\u00a0die\u00a0Quelle\u00a0unklar\u00a0blieb.\u00a0Bei\u00a02\u00a0F\u00e4llen\u00a0hat\u00a0\ndemnach \u00a0eine\u00a0symptomatische \u00a0Impfvirus \u2010\u00dcbertragung \u00a0stattgefunden. \u00a0\nIn\u00a0Australien, \u00a0wo\u00a02007\u00a0die\u00a0RV\u2010Impfung\u00a0eingef\u00fchrt \u00a0wurde,\u00a0ist\u00a0im\u00a0Zeitraum\u00a0von\u00a02007\u00a0bis\u00a02010\u00a0ein\u00a0\nMonitoring \u2010System\u00a0der\u00a0Impfvirus \u2010Ausscheidung \u00a0eingerichtet \u00a0worden.\u00a0Donato\u00a0et\u00a0al.\u00a0berichten, \u00a0dass\u00a010\u00a0\n\u00a0RotaTeq\u00ae \u2010Impfvirus \u00a0oder\u00a0eine\u00a0urspr\u00fcnglich \u00a0nicht\u00a0im\u00a0Impfstoff\u00a0enthaltene \u00a0Reassortante \u00a0bei\u00a013\u00a0(21,3%)\u00a0\nvon\u00a061\u00a0S\u00e4uglingen \u00a0nachgewiesen \u00a0wurde,\u00a0die\u00a0im\u00a0Zeitraum\u00a0von\u00a02\u00a0Wochen\u00a0nach\u00a0der\u00a0Impfung\u00a0an\u00a0einer\u00a0\nAGE\u00a0erkrankten \u00a0und\u00a0bei\u00a03\u00a0(0,7%)\u00a0von\u00a0460\u00a0AGE\u2010F\u00e4llen\u00a0(Information \u00a0zu\u00a0vorangegangener \u00a0Impfung\u00a0\nunbekannt), \u00a0die\u00a0im\u00a0Rahmen\u00a0des\u00a0RV\u2010Surveillance \u2010Programms \u00a0untersucht \u00a0wurden\u00a0[43,\u00a044].\u00a0Bei\u00a06\u00a0\n(37,5%)\u00a0der\u00a016\u00a0identifizierten \u00a0F\u00e4lle\u00a0handelte\u00a0es\u00a0sich\u00a0um\u00a0einen\u00a0vom\u00a0Impfstoff\u00a0abgeleiteten \u00a0vdG1P[8] \u2010\nStamm,\u00a0der\u00a0eine\u00a0neue,\u00a0nicht\u00a0im\u00a0Impfstoff \u00a0enthaltene \u00a0Reassortante \u00a0darstellt.\u00a0Bei\u00a0den\u00a0restlichen \u00a010\u00a0\nF\u00e4llen\u00a0handelte\u00a0es\u00a0sich\u00a0um\u00a0RotaTeq\u00ae \u2010Impfst\u00e4mme. \u00a0\nNach\u00a0Einf\u00fchrung \u00a0der\u00a0RV\u2010Standardimpfung \u00a0wurde\u00a0in\u00a0Finnland\u00a0zwischen\u00a0September \u00a02009\u00a0und\u00a0August\u00a0\n2011\u00a0eine\u00a0prospektive \u00a0Studie\u00a0zur\u00a0Ursache\u00a0akuter\u00a0Gastroenteritiden \u00a0bei\u00a0Kindern\u00a0<16\u00a0Jahren,\u00a0die\u00a0eine\u00a0\nNotfallaufnahme \u00a0aufsuchten, \u00a0durchgef\u00fchrt \u00a0[45].\u00a0Von\u00a0den\u00a0316\u00a0untersuchten \u00a0Patienten \u00a0waren\u00a079\u00a0\n(25%)\u00a0RV\u2010positiv;\u00a0wovon\u00a017\u00a0Untersuchte \u00a0mindestens \u00a0eine\u00a0Dosis\u00a0RotaTeq\u00ae \u00a0erhalten\u00a0hatten.\u00a0In\u00a03\u00a0F\u00e4llen\u00a0\nwurde\u00a0eine\u00a0Impfstoff \u2010verwandte \u00a0neue\u00a0Doppel\u2010Reassortante \u00a0nachgewiesen. \u00a0Alle\u00a0Patienten \u00a0waren\u00a0\nimmunkompetent \u00a0und\u00a0der\u00a0Verlauf\u00a0der\u00a0GE\u00a0war\u00a0mild.\u00a0\nIn\u00a0einer\u00a0aktuellen \u00a0Publikation \u00a0aus\u00a0den\u00a0USA\u00a0wird\u00a0\u00fcber\u00a0Erfahrungen \u00a0der\u00a0Impfung\u00a0mit\u00a0RotaTeq\u00ae \u00a0auf\u00a0\neiner\u00a0Neugeborenen \u2010Intensivstation \u00a0berichtet\u00a0[46].\u00a0S\u00e4uglinge, \u00a0die\u00a0nach\u00a0ihrem\u00a0chronologischen \u00a0Alter\u00a0\nin\u00a0das\u00a0Zeitfenster \u00a0der\u00a0Impfung\u00a0passten\u00a0und\u00a0enteral\u00a0ern\u00e4hrt\u00a0wurden,\u00a0wurden\u00a0routinem\u00e4\u00dfig \u00a0mit\u00a0\nRotaTeq\u00ae \u00a0geimpft.\u00a0F\u00fcr\u00a0den\u00a0Zeitraum\u00a0von\u00a02008\u00a0bis\u00a02010\u00a0wurde\u00a0in\u00a0einer\u00a0r\u00fcckblickenden \u00a0Analyse\u00a0\nuntersucht, \u00a0wie\u00a0geimpfte\u00a0Kinder\u00a0die\u00a0Impfung\u00a0vertragen \u00a0hatten\u00a0und\u00a0ob\u00a0ungeimpfte \u00a0Kinder\u00a0im\u00a0Umfeld\u00a0\nder\u00a0geimpften \u00a0Kinder\u00a0im\u00a0Zeitraum\u00a0von\u00a015\u00a0Tagen\u00a0nach\u00a0der\u00a0Impfung\u00a0gastrointestinale \u00a0Symptome \u00a0\nentwickelt \u00a0hatten.\u00a0Die\u00a0Impfung\u00a0wurde\u00a0gut\u00a0vertragen. \u00a0Der\u00a0Zustand\u00a0von\u00a076%\u00a0der\u00a096\u00a0geimpften \u00a0Kinder\u00a0\nwar\u00a0nach\u00a0der\u00a0Impfung\u00a0asymptomatisch \u00a0oder\u00a0unver\u00e4ndert \u00a0und\u00a0bei\u00a0den\u00a0\u00fcbrigen\u00a0S\u00e4uglingen \u00a0waren\u00a0die\u00a0\n\u00c4nderungen \u00a0des\u00a0klinischen \u00a0Status\u00a0nicht\u00a0von\u00a0der\u00a0Impfung\u00a0verursacht. \u00a0Von\u00a0den\u00a0801\u00a0Ungeimpften \u00a0im\u00a0\nUmfeld\u00a0hatte\u00a0sich\u00a0bei\u00a01,2%\u00a0das\u00a0klinische\u00a0Zustandsbild \u00a0zwar\u00a0ver\u00e4ndert; \u00a0dies\u00a0konnte\u00a0aber\u00a0der\u00a0Impfung\u00a0\nnicht\u00a0zugeschrieben \u00a0werden.\u00a0\u00a0\nEmpfehlungen \tnationaler \tImpfkommissionen \tzur\tRV\u2010Impfung \tvon\tFr\u00fchgeborenen \t\nIn\u00a0den\u00a0USA\u00a0wird\u00a0die\u00a0RV\u2010Impfung\u00a0von\u00a0Fr\u00fchgeborenen \u00a0erst\u00a0zum\u00a0Zeitpunkt \u00a0der\u00a0Entlassung \u00a0von\u00a0der\u00a0\nNeugeborenen \u2010Intensivstation \u00a0empfohlen, \u00a0soweit\u00a0sie\u00a0klinisch\u00a0stabil\u00a0sind\u00a0und\u00a0sich\u00a0im\u00a0empfohlenen \u00a0\nAlterszeitfenster \u00a0(42\u2010104\u00a0Tage\u00a0alt)\u00a0befinden\u00a0[17,\u00a023,\u00a032].\u00a0Nach\u00a0Einsch\u00e4tzungen \u00a0des\u00a0amerikanischen \u00a0\nImpfberatungsausschusses \u00a0(ACIP)\u00a0\u00fcberwiegen \u00a0das\u00a0Risiko\u00a0der\u00a0Ausscheidung \u00a0von\u00a0RV\u2010Impfviren \u00a0und\u00a0die\u00a0\npotenzielle \u00a0\u00dcbertragung \u00a0auf\u00a0andere\u00a0gef\u00e4hrdete \u00a0Kinder\u00a0die\u00a0Vorteile\u00a0der\u00a0Impfung\u00a0w\u00e4hrend\u00a0des\u00a0\nAufenthalts \u00a0auf\u00a0der\u00a0Intensivstation. \u00a0\u00a0\nNach\u00a0den\u00a0Empfehlungen \u00a0des\u00a0kanadischen \u00a0Impfkomitees \u00a0ist\u00a0die\u00a0RV\u2010Impfung\u00a0von\u00a0Fr\u00fchgeborenen \u00a0\nempfohlen, \u00a0wenn\u00a0die\u00a0S\u00e4uglinge \u00a0gesund\u00a0sind,\u00a0nicht\u00a0hospitalisiert \u00a0sind,\u00a0und\u00a0sie\u00a0entsprechend \u00a0ihres\u00a0\nchronologischen \u00a0Alters\u00a0geimpft\u00a0werden\u00a0k\u00f6nnen\u00a0[47].\u00a0\u00a0\nIn\u00a0den\u00a0australischen \u00a0Impfempfehlungen \u00a0zur\u00a0RV\u2010Impfung\u00a0wird\u00a0herausgestellt, \u00a0dass\u00a0Fr\u00fchgeborene, \u00a0\nwenn\u00a0sie\u00a0klinisch\u00a0stabil\u00a0sind,\u00a0entsprechend \u00a0ihres\u00a0chronologischen \u00a0Alters\u00a0ab\u00a0dem\u00a0Alter\u00a0von\u00a06\u00a0Wochen\u00a0\ngeimpft\u00a0werden\u00a0sollen\u00a0[48,\u00a049].\u00a0Solange\u00a0Standard\u2010Infektionsschutzma\u00dfnahmen \u00a0eingehalten \u00a0werden,\u00a0\nwird\u00a0die\u00a0Gabe\u00a0von\u00a0RV\u2010Impfstoffen \u00a0an\u00a0hospitalisierte \u00a0S\u00e4uglinge, \u00a0miteingeschlossen \u00a0sind\u00a0auch\u00a0\nhospitalisierte \u00a0Fr\u00fchgeborene, \u00a0als\u00a0wenig\u00a0risikoreich \u00a0im\u00a0Hinblick\u00a0auf\u00a0die\u00a0\u00dcbertragung \u00a0von\u00a0Impfviren \u00a0\neingesch\u00e4tzt. \u00a0Vorausgesetzt, \u00a0dass\u00a0der\u00a0S\u00e4ugling\u00a0klinisch\u00a0stabil\u00a0ist,\u00a0sollte\u00a0die\u00a0Impfung\u00a0nicht\u00a0\naufgeschoben \u00a0werden,\u00a0insbesondere, \u00a0wenn\u00a0die\u00a0Verz\u00f6gerung \u00a0der\u00a0Impfung\u00a0dazu\u00a0f\u00fchrt,\u00a0dass\u00a0der\u00a0\nS\u00e4ugling\u00a0die\u00a0obere\u00a0Altersgrenze \u00a0f\u00fcr\u00a0die\u00a0Impfung\u00a0\u00fcberschreitet. \u00a0\u00a011\u00a0\n\u00a0Werden\u00a0k\u00fcrzlich\u00a0RV\u2010geimpfte\u00a0S\u00e4uglinge \u00a0station\u00e4r\u00a0aufgenommen, \u00a0so\u00a0werden\u00a0Standard\u2010\nHygienema\u00dfnahmen \u00a0als\u00a0ausreichend \u00a0angesehen, \u00a0um\u00a0eine\u00a0Impfvirus \u2010\u00dcbertragung \u00a0zu\u00a0verhindern. \u00a0\nIn\u00a0den\u00a0Handlungsempfehlungen \u00a0des\u00a0englischen \u00a0Gesundheitsdienstes \u00a0zur\u00a0Implementierung \u00a0des\u00a0RV\u2010\nImpfprogramms \u00a0vom\u00a0Juli\u00a02013\u00a0und\u00a0im\u00a0Kapitel\u00a0\u201eRotavirus\u201c \u00a0des\u00a0Green\u00a0Book\u00a0wird\u00a0darauf\u00a0hingewiesen, \u00a0\ndass\u00a0es\u00a0wichtig\u00a0ist,\u00a0S\u00e4uglinge \u00a0entsprechend \u00a0ihres\u00a0chronologischen \u00a0Alters\u00a0zu\u00a0impfen\u00a0[50,\u00a051].\u00a0Da\u00a0der\u00a0\nNutzen\u00a0der\u00a0Impfung\u00a0f\u00fcr\u00a0diese\u00a0Kinder\u00a0besonders \u00a0hoch\u00a0ist,\u00a0sollte\u00a0die\u00a0Impfung\u00a0von\u00a0klinisch\u00a0stabilen\u00a0\nS\u00e4uglingen \u00a0auf\u00a0keinen\u00a0Fall\u00a0unterbleiben \u00a0oder\u00a0verz\u00f6gert \u00a0werden,\u00a0insbesondere \u00a0dann\u00a0nicht,\u00a0wenn\u00a0\ndadurch\u00a0riskiert\u00a0wird,\u00a0dass\u00a0das\u00a0Kind\u00a0bei\u00a0sp\u00e4terer\u00a0Impfung\u00a0die\u00a0Altersgrenze \u00a0\u00fcberschritten \u00a0haben\u00a0wird.\u00a0\nEs\u00a0wird\u00a0weiterhin \u00a0festgestellt, \u00a0dass\u00a0die\u00a0Verabreichung \u00a0der\u00a0RV\u2010Impfung\u00a0an\u00a0hospitalisierte \u00a0S\u00e4uglinge, \u00a0\ninklusive\u00a0Fr\u00fchgeborener \u00a0auf\u00a0Neugeborenen \u2010Stationen, \u00a0wahrscheinlich \u00a0nur\u00a0ein\u00a0geringes\u00a0\n\u00dcbertragungsrisiko \u00a0f\u00fcr\u00a0Impfviren \u00a0birgt,\u00a0wenn\u00a0Standardhygienema\u00dfnahmen \u00a0eingehalten \u00a0werden.\u00a0Bei\u00a0\nAufnahme \u00a0von\u00a0k\u00fcrzlich\u00a0geimpften \u00a0Kindern\u00a0reichen\u00a0ebenso\u00a0Standardhygienema\u00dfnahmen \u00a0aus,\u00a0um\u00a0\neine\u00a0Weiterverbreitung \u00a0im\u00a0Krankenhaus \u00a0zu\u00a0verhindern. \u00a0\nFr\u00fchgeborene \u00a0sollten,\u00a0solange\u00a0sie\u00a0hospitalisiert \u00a0sind,\u00a0nach\u00a0der\u00a0ersten\u00a0Impfung\u00a0f\u00fcr\u00a048\u00a0bis\u00a072\u00a0Stunden\u00a0\ngrunds\u00e4tzlich \u00a0kardio\u2010respiratorisch \u00a0\u00fcberwacht \u00a0werden.\u00a0Bei\u00a0Auff\u00e4lligkeiten \u00a0sollte\u00a0auch\u00a0die\u00a0zweite\u00a0\nImpfung\u00a0unter\u00a0kardio\u2010respiratorischem \u00a0Monitoring \u00a0erfolgen.\u00a0Dies\u00a0entspricht \u00a0auch\u00a0den\u00a0Vorgaben \u00a0in\u00a0\nden\u00a0Fachinformationen \u00a0der\u00a0beiden\u00a0RV\u2010Impfstoffe \u00a0und\u00a0entsprechenden \u00a0Empfehlungen \u00a0in\u00a0Deutschland \u00a0\n[52].\u00a0\u00a0\nStudie\tzu\tvers\u00e4umten \tRV\u2010Impfungen \tbei\tFr\u00fchgeborenen \t\nEine\u00a0Studie\u00a0von\u00a0Stumpf\u00a0et\u00a0al.\u00a0untersuchte \u00a0das\u00a0Impfmanagement \u00a0hinsichtlich \u00a0der\u00a0Inanspruchnahme \u00a0\nvon\u00a0RV\u2010Impfungen \u00a0bei\u00a0fr\u00fchgeborenen \u00a0S\u00e4uglingen, \u00a0die\u00a0nach\u00a0der\u00a0Geburt\u00a0l\u00e4nger\u00a0station\u00e4r\u00a0behandelt \u00a0\nwerden\u00a0mussten.\u00a0In\u00a0dieser\u00a0prospektiven \u00a0Beobachtungsstudie, \u00a0die\u00a0\u00fcber\u00a0einen\u00a0Zeitraum\u00a0von\u00a02\u00a0Jahren\u00a0\n(Mai\u00a02008\u2010April\u00a02010)\u00a0zur\u00a0RV\u2010Impfung\u00a0von\u00a0S\u00e4uglingen \u00a0mit\u00a0sehr\u00a0niedrigem \u00a0Geburtsgewicht \u00a0\ndurchgef\u00fchrt \u00a0wurde,\u00a0zeigte\u00a0sich,\u00a0dass\u00a0von\u00a0213\u00a0beobachteten \u00a0Kindern\u00a0135\u00a0(63%)\u00a0keine\u00a0RV\u2010Impfung\u00a0\nbekamen. \u00a0Darunter\u00a0waren\u00a0S\u00e4uglinge, \u00a0die\u00a0zum\u00a0Zeitpunkt \u00a0der\u00a0Entlassung \u00a0noch\u00a0zu\u00a0jung\u00a0(56/213;\u00a026%)\u00a0\noder\u00a0bereits\u00a0zu\u00a0alt\u00a0(48/213;\u00a023%)\u00a0waren,\u00a0um\u00a0eine\u00a0RV\u2010Impfung\u00a0zu\u00a0bekommen \u00a0oder\u00a0eine\u00a0m\u00f6gliche\u00a0\nImpfung\u00a0war\u00a0aus\u00a0anderen\u00a0Gr\u00fcnden\u00a0vers\u00e4umt \u00a0worden\u00a0(35/213;\u00a016%)\u00a0[53].\u00a0Es\u00a0wird\u00a0explizit\u00a0darauf\u00a0\nhingewiesen, \u00a0dass\u00a0die\u00a0Empfehlung \u00a0der\u00a0ACIP,\u00a0S\u00e4uglinge \u00a0solange\u00a0sie\u00a0auf\u00a0der\u00a0Intensivstation \u00a0behandelt \u00a0\nwerden,\u00a0nicht\u00a0zu\u00a0impfen,\u00a0nicht\u00a0evidenz\u2010basiert\u00a0ist,\u00a0und\u00a0dass\u00a0Sicherheitsstudien \u00a0in\u00a0diesem\u00a0Kollektiv\u00a0\ndringend\u00a0notwendig \u00a0sind.\u00a0\nZusammenfassung \tder\tErgebnisse \t\nDie\u00a0Ergebnisse \u00a0zum\u00a0Auftreten \u00a0von\u00a0unerw\u00fcnschten \u00a0Arzneimittelwirkungen \u00a0nach\u00a0der\u00a0RV\u2010Impfung\u00a0von\u00a0\nFr\u00fchgeborenen \u00a0aus\u00a0den\u00a0Zulassungsstudien \u00a0best\u00e4tigen \u00a0den\u00a0beiden\u00a0RV\u2010Impfstoffen \u00a0ein\u00a0gutes\u00a0\nSicherheitsprofil \u00a0f\u00fcr\u00a0diese\u00a0Zielgruppe. \u00a0Die\u00a0Datenlage \u00a0f\u00fcr\u00a0sehr\u00a0unreife\u00a0Fr\u00fchgeborene \u00a0mit\u00a0einem\u00a0\nGestationsalter \u00a0von\u00a025\u00a0bis\u00a031\u00a0SSW\u00a0ist\u00a0jedoch\u00a0eingeschr\u00e4nkt, \u00a0da\u00a0die\u00a0untersuchten \u00a0Studienkollektive \u00a0in\u00a0\ndieser\u00a0Altersgruppe \u00a0klein\u00a0waren.\u00a0Die\u00a0klinische\u00a0Wirksamkeit \u00a0zum\u00a0Schutz\u00a0vor\u00a0schweren \u00a0RVGE\u00a0bei\u00a0\nFr\u00fchgeborenen \u00a0wurde\u00a0in\u00a0Zulassungsstudien \u00a0von\u00a0RotaTeq\u00ae \u00a0dokumentiert, \u00a0w\u00e4hrend\u00a0f\u00fcr\u00a0Rotarix\u00ae\u00a0\nausschlie\u00dflich \u00a0Immunogenit\u00e4tsdaten \u00a0als\u00a0Surrogat\u00a0f\u00fcr\u00a0die\u00a0Protektion \u00a0existieren. \u00a0\u00a0\nEs\u00a0gibt\u00a0nur\u00a0einzelne\u00a0Studien\u00a0mit\u00a0wenigen\u00a0Probanden, \u00a0welche\u00a0die\u00a0Impfvirusausscheidung \u00a0bei\u00a0\nFr\u00fchgeborenen \u00a0untersucht \u00a0und\u00a0auch\u00a0quantifiziert \u00a0haben,\u00a0so\u00a0dass\u00a0f\u00fcr\u00a0die\u00a0Risikobeurteilung \u00a0\ninsbesondere \u00a0Studien\u00a0bei\u00a0zum\u00a0Termin\u00a0Geborenen \u00a0herangezogen \u00a0wurden.\u00a0Mittels\u00a0RT\u2010PCR\u00a0kann,\u00a0\nunabh\u00e4ngig \u00a0vom\u00a0verwendeten \u00a0Impfstoff, \u00a0innerhalb \u00a0von\u00a028\u00a0Tagen\u00a0nach\u00a0der\u00a01.\u00a0Impfstoffdosis, \u00a0und\u00a0\ninnerhalb \u00a0von\u00a015\u00a0Tagen\u00a0nach\u00a0der\u00a02.\u00a0Rotarix\u00ae\u2010Impfstoffdosis, \u00a0sowie\u00a0innerhalb \u00a0von\u00a014\u00a0Tagen\u00a0nach\u00a0der\u00a012\u00a0\n\u00a02.\u00a0und\u00a03.\u00a0RotaTeq\u00ae \u2010Impfstoffdosis \u00a0Impfvirus \u00a0im\u00a0Stuhl\u00a0nachgewiesen \u00a0werden.\u00a0Die\u00a0maximale \u00a0\nAusscheidung \u00a0wird\u00a0jeweils\u00a0zwischen\u00a0dem\u00a06.\u00a0bis\u00a08.\u00a0Tag\u00a0nach\u00a0Impfung\u00a0erreicht.\u00a0Obwohl\u00a0die\u00a0\nAusscheidungsraten \u00a0nicht\u00a0signifikant \u00a0unterschiedlich \u00a0sind,\u00a0ist\u00a0die\u00a0ausgeschiedene \u00a0Virusmenge \u00a0nach\u00a0\nRotarix\u00ae\u00a0signifikant \u00a0h\u00f6her.\u00a0Da\u00a0in\u00a0vielen\u00a0Studien\u00a0nur\u00a0ein\u00a0EIA\u00a0zum\u00a0Nachweis \u00a0der\u00a0Impfvirusausscheidung \u00a0\neingesetzt \u00a0wurde,\u00a0wird\u00a0die\u00a0tats\u00e4chliche \u00a0Virusausscheidung \u00a0aufgrund\u00a0der\u00a0Nachweisgrenze \u00a0des\u00a0EIA\u00a0\nsehr\u00a0wahrscheinlich \u00a0untersch\u00e4tzt. \u00a0Die\u00a0RT\u2010PCR\u00a0ist\u00a03\u00a0bis\u00a04\u00a0log\u2010Stufen\u00a0empfindlicher \u00a0und\u00a0kann\u00a0schon\u00a0\ndeutlich\u00a0geringere \u00a0Viruskonzentrationen \u00a0nachweisen \u00a0[34].\u00a0Inwieweit \u00a0diese\u00a0geringen\u00a0Virusmengen \u00a0zu\u00a0\neiner\u00a0\u00dcbertragung \u00a0auf\u00a0empf\u00e4ngliche \u00a0Kontaktpersonen \u00a0f\u00fchren,\u00a0ist\u00a0fraglich.\u00a0Die\u00a0unterschiedliche \u00a0\nVirusmenge \u00a0die\u00a0nach\u00a0Rotarix\u00ae\u2010\u00a0und\u00a0RotaTeq\u00ae \u2010Impfung\u00a0ausgeschieden \u00a0wird,\u00a0l\u00e4sst\u00a0sich\u00a0durch\u00a0die\u00a0\nverschiedene \u00a0Impfstoffzusammensetzung \u00a0erkl\u00e4ren.\u00a0Rotarix\u00ae\u00a0beruht\u00a0auf\u00a0einem\u00a0humanen \u00a0Virusstamm, \u00a0\nder\u00a0gut\u00a0im\u00a0Darm\u00a0repliziert. \u00a0Im\u00a0Gegensatz \u00a0dazu\u00a0beruht\u00a0RotaTeq\u00ae \u00a0auf\u00a0einer\u00a0Kombination \u00a0aus\u00a05\u00a0bovinen\u2010\nhumanen \u2010Virus\u2010Reassortanten, \u00a0die\u00a0weniger\u00a0gut\u00a0im\u00a0Darm\u00a0replizieren. \u00a0\u00a0\nDeutlich\u00a0seltener\u00a0als\u00a0die\u00a0Ausscheidung \u00a0von\u00a0RotaTeq\u00ae \u2010Impfviren \u00a0ist\u00a0die\u00a0Ausscheidung \u00a0von\u00a0Impfstoff \u2010\nabgeleiteten \u00a0Viren\u00a0(vdG1P[8]). \u00a0Es\u00a0sind\u00a0bisher\u00a0nur\u00a0Einzelf\u00e4lle \u00a0berichtet\u00a0worden.\u00a0Die\u00a0klinische\u00a0\nBedeutung \u00a0solcher\u00a0Ereignisse \u00a0muss\u00a0weiter\u00a0untersucht \u00a0werden.\u00a0Dazu\u00a0geh\u00f6rt\u00a0die\u00a0Kl\u00e4rung,\u00a0in\u00a0welchem\u00a0\nAusma\u00df\u00a0\u00fcbertragene \u00a0Impfviren \u00a0bzw.\u00a0vom\u00a0Impfstoff \u2010abgeleitete \u00a0Viren\u00a0auch\u00a0zu\u00a0einer\u00a0Erkrankung \u00a0der\u00a0\ninfizierten \u00a0Kinder\u00a0f\u00fchren\u00a0und\u00a0ob\u00a0es\u00a0hier\u00a0Unterschiede \u00a0im\u00a0Manifestationsindex \u00a0bei\u00a0\nimmunkompetenten \u00a0und\u00a0immundefizienten \u00a0Personen \u00a0gibt.\u00a0\nTrotz\u00a0der\u00a0routinem\u00e4\u00dfigen \u00a0Verabreichung \u00a0von\u00a0RV\u2010Impfstoffen \u00a0in\u00a0vielen\u00a0L\u00e4ndern\u00a0weltweit\u00a0und\u00a0des\u00a0\nregelm\u00e4\u00dfigen \u00a0Vorkommens \u00a0einer\u00a0Ausscheidung \u00a0von\u00a0Impfviren \u00a0sind\u00a0jedoch\u00a0bisher\u00a0nur\u00a0wenige,\u00a0\nzumeist\u00a0einzelne\u00a0Fallberichte \u00a0von\u00a0Impfvirus \u2010\u00dcbertragungen \u00a0publiziert \u00a0worden.\u00a0Dies\u00a0unterst\u00fctzt \u00a0die\u00a0\nauch\u00a0in\u00a0den\u00a0Zulassungsstudien \u00a0dokumentierte \u00a0Sicherheit \u00a0der\u00a0oralen\u00a0RV\u2010Impfung.\u00a0Systematisch \u00a0wurde\u00a0\ndie\u00a0\u00dcbertragung \u00a0von\u00a0Impfviren \u00a0in\u00a0der\u00a0Studie\u00a0von\u00a0Rivera\u00a0untersucht, \u00a0wo\u00a0auf\u00a019%\u00a0der\u00a0ungeimpften \u00a0\nZwillinge\u00a0(Gestationsalter \u00a0\u226532\u00a0Wochen)\u00a0eine\u00a0Virus\u00fcbertragung \u00a0beobachtet \u00a0wurde\u00a0[40].\u00a0Bei\u00a0keinem\u00a0\nder\u00a0F\u00e4lle,\u00a0an\u00a0die\u00a0Impfviren \u00a0\u00fcbertragen \u00a0wurden,\u00a0trat\u00a0in\u00a0der\u00a0Folge\u00a0eine\u00a0Gastroenteritis \u2010Symptomatik \u00a0\nauf.\u00a0Nach\u00a0der\u00a0horizontalen \u00a0\u00dcbertragung \u00a0von\u00a0Impfviren \u00a0konnte\u00a0bei\u00a0einem\u00a0Teil\u00a0der\u00a0F\u00e4lle\u00a0eine\u00a0\nSerokonversion \u00a0und\u00a0damit\u00a0vermutlich \u00a0ein\u00a0durch\u00a0das\u00a0Impfvirus \u00a0induzierter \u00a0Schutz\u00a0(ohne\u00a0eigene\u00a0\nImpfung)\u00a0vor\u00a0einer\u00a0Wildtyp\u2010RV\u2010Infektion\u00a0nachgewiesen \u00a0werden.\u00a0Hinsichtlich \u00a0der\u00a0Ausscheidung \u00a0\nzeigten\u00a0Smith\u00a0et\u00a0al.,\u00a0dass\u00a0auch\u00a0fr\u00fchgeborene \u00a0S\u00e4uglinge \u00a0RV\u2010Impfvirus \u00a0nach\u00a0Impfung\u00a0\u00fcber\u00a0einen\u00a0\nZeitraum\u00a0von\u00a02\u00a0Wochen\u00a0ausscheiden, \u00a0jedoch\u00a0ohne\u00a0dass\u00a0Haushaltkontaktpersonen \u00a0im\u00a0Umfeld\u00a0in\u00a0der\u00a0\nFolge\u00a0erkrankten \u00a0[38].\u00a0Allerdings \u00a0wurden\u00a0die\u00a0Studienteilnehmer \u00a0bei\u00a0Entlassung \u00a0aus\u00a0der\u00a0Klinik\u00a0geimpft\u00a0\nund\u00a0die\u00a0Ergebnisse \u00a0sind\u00a0deshalb\u00a0nicht\u00a0unbedingt \u00a0auf\u00a0die\u00a0Bedingungen \u00a0in\u00a0Kliniken\u00a0einschlie\u00dflich \u00a0deren\u00a0\nIntensivstationen \u00a0\u00fcbertragbar. \u00a0\u00a0\nEine\u00a0Ausscheidung \u00a0von\u00a0Viren\u00a0nach\u00a0der\u00a0Impfung\u00a0ist\u00a0ein\u00a0unvermeidbarer \u00a0Vorgang,\u00a0da\u00a0er\u00a0die\u00a0\nVirusreplikation \u00a0anzeigt.\u00a0Bei\u00a0Impfviren \u00a0handelt\u00a0es\u00a0sich\u00a0um\u00a0attenuierte \u00a0Virusst\u00e4mme, \u00a0die\u00a0\u2013wenn\u00a0\n\u00fcberhaupt\u2013 \u00a0eine\u00a0Symptomatik \u00a0verursachen, \u00a0die\u00a0typischerweise \u00a0weniger\u00a0schwer\u00a0verl\u00e4uft\u00a0als\u00a0bei\u00a0einer\u00a0\nWildvirusinfektion. \u00a0Aufgrund \u00a0des\u00a0geringen\u00a0\u00dcbertragungs \u2010\u00a0und\u00a0anschlie\u00dfend \u00a0ebenfalls\u00a0geringen\u00a0\nErkrankungsrisikos \u00a0soll,\u00a0wie\u00a0die\u00a0Amerikanische \u00a0Impfkommission \u00a0(ACIP)\u00a0feststellt, \u00a0eine\u00a0RV\u2010Impfung\u00a0\nvon\u00a0S\u00e4uglingen \u00a0im\u00a0Umfeld\u00a0von\u00a0Immunsupprimierten \u00a0nicht\u00a0unterbleiben. \u00a0In\u00a0Analogie\u00a0dazu\u00a0sollte\u00a0auch\u00a0\ndas\u00a0Impfen\u00a0von\u00a0S\u00e4uglingen \u00a0im\u00a0Krankenhaus \u00a0als\u00a0unkritisch \u00a0angesehen \u00a0werden.\u00a0\nDie\u00a0Ausscheidung \u00a0von\u00a0Impfviren \u00a0kann\u00a0sogar\u00a0als\u00a0Vorteil\u00a0angesehen \u00a0werden,\u00a0da\u00a0es\u00a0Ungeimpften \u00a0im\u00a0\nUmfeld\u00a0die\u00a0Chance\u00a0gibt,\u00a0durch\u00a0den\u00a0Kontakt\u00a0zu\u00a0nicht\u2010pathogenen \u00a0Impfviren \u00a0ebenfalls\u00a0einen\u00a0Schutz\u00a0vor\u00a0\nWildvirus \u2010Infektion\u00a0zu\u00a0erwerben. \u00a0Im\u00a0Rahmen\u00a0der\u00a0Polio\u2010Eradikation \u00a0war\u00a0die\u00a0F\u00e4higkeit\u00a0der\u00a0oralen\u00a0Polio\u201013\u00a0\n\u00a0Vakzine,\u00a0indirekt\u00a0suszeptible \u00a0Personen \u00a0\u00fcber\u00a0die\u00a0\u00dcbertragung \u00a0von\u00a0ausgeschiedenen \u00a0Impfviren \u00a0zu\u00a0\nimmunisieren \u00a0und\u00a0damit\u00a0einen\u00a0breiteren \u00a0Immunit\u00e4t \u00a0in\u00a0der\u00a0Bev\u00f6lkerung \u00a0zu\u00a0vermitteln, \u00a0ein\u00a0erkl\u00e4rtes\u00a0\nZiel\u00a0[2].\u00a0\u00a0\nEs\u00a0soll\u00a0in\u00a0diesem\u00a0Zusammenhang \u00a0noch\u00a0einmal\u00a0explizit\u00a0darauf\u00a0hingewiesen \u00a0werden,\u00a0dass\u00a0neben\u00a0der\u00a0\nausreichenden \u00a0personellen \u00a0Ausstattung, \u00a0insbesondere \u00a0im\u00a0Bereich\u00a0der\u00a0Pflege,\u00a0zur\u00a0Pr\u00e4vention \u00a0von\u00a0\nnosokomialen \u00a0RV\u2010Infektionen \u00a0die\u00a0Einhaltung \u00a0bestimmter \u00a0Standardhygienema\u00dfnahmen \u00a0unerl\u00e4sslich \u00a0\nist\u00a0[54,\u00a055].\u00a0Dazu\u00a0z\u00e4hlen\u00a0neben\u00a0der\u00a0\u00fcblichen\u00a0hygienischen \u00a0H\u00e4ndedesinfektion \u00a0auch\u00a0Schutzkittel \u00a0und\u00a0\nHandschuhe \u00a0beim\u00a0Windelwechsel. \u00a0Die\u00a0verwendeten \u00a0H\u00e4nde\u2010\u00a0und\u00a0Fl\u00e4chendesinfektionsmittel \u00a0sollten\u00a0\neine\u00a0Wirksamkeit \u00a0gegen\u00fcber \u00a0Rotaviren \u00a0haben.\u00a0Das\u00a0sog.\u00a0\u201eK\u00e4nguruhen\u201c \u00a0ist\u00a0mit\u00a0Windel\u00a0und\u00a0unter\u00a0\nBeachtung \u00a0der\u00a0H\u00e4ndehygiene \u00a0durch\u00a0die\u00a0Eltern\u00a0auch\u00a0nach\u00a0Impfung\u00a0m\u00f6glich.\u00a0Eine\u00a0r\u00e4umliche \u00a0Isolierung \u00a0\nbzw.\u00a0Kohortierung \u00a0kann\u00a0entsprechend \u00a0den\u00a0lokalen\u00a0r\u00e4umlichen \u00a0Gegebenheiten \u00a0in\u00a0Absprache \u00a0mit\u00a0den\u00a0\nzust\u00e4ndigen \u00a0Hygienikern \u00a0erwogen\u00a0werden.\u00a0\nNach\u00a0Abw\u00e4gung \u00a0von\u00a0Nutzen\u00a0und\u00a0Risiken\u00a0der\u00a0RV\u2010Impfung\u00a0kann\u00a0die\u00a0zeitgerechte \u00a0RV\u2010Impfung\u00a0auch\u00a0f\u00fcr\u00a0\nhospitalisierte \u00a0Fr\u00fchgeborene \u00a0und\u00a0andere\u00a0reifgeborene \u00a0aber\u00a0station\u00e4r\u00a0versorgte \u00a0S\u00e4uglinge \u00a0\nentsprechend \u00a0ihrem\u00a0chronologischen \u00a0Alter\u00a0empfohlen \u00a0werden.\u00a0\n\u00a0Korrespondenzadresse: \u00a0\nDeutsche \u00a0Akademie \u00a0f\u00fcr\u00a0Kinder\u2010\u00a0und\u00a0Jugendmedizin \u00a0e.V.\u00a0\u00a0\nProf.\u00a0Dr.\u00a0med.\u00a0Manfred\u00a0Gahr,\u00a0Generalsekret\u00e4r \u00a0\nChausseestr. \u00a0128/129,\u00a010115\u00a0Berlin\u00a0\u00a0\nTel.:\u00a0030.40005880, \u00a0Fax.:\u00a0030.400058888 \u00a0\u00a0\nE\u2010Mail:\u00a0kontakt@dakj.de ,\u00a0www.dakj.de \u00a0\n\u00a0\u00a014\u00a0\n\u00a0Literatur \t\n1.\u00a0 Anderson \u00a0EJ\u00a0(2008)\u00a0Rotavirus \u00a0vaccines:\u00a0viral\u00a0shedding\u00a0and\u00a0risk\u00a0of\u00a0transmission. \u00a0The\u00a0Lancet\u00a0\nInfectious \u00a0Diseases\u00a08:642\u2010649\u00a0\n2.\u00a0 Alexander \u00a0LN,\u00a0Seward\u00a0JF,\u00a0Santibanez \u00a0TA,\u00a0et\u00a0al.\u00a0(2004)\u00a0Vaccine\u00a0policy\u00a0changes\u00a0and\u00a0\nepidemiology \u00a0of\u00a0poliomyelitis \u00a0in\u00a0the\u00a0United\u00a0States.\u00a0JAMA\u00a0292:1696 \u20101701\u00a0\n3.\u00a0 Koch\u00a0J,\u00a0Wiese\u2010Posselt\u00a0M,\u00a0Remschmidt \u00a0C,\u00a0et\u00a0al.\u00a0(2013)\u00a0Background \u00a0paper\u00a0to\u00a0the\u00a0\nrecommendation \u00a0for\u00a0routine\u00a0rotavirus\u00a0vaccination \u00a0of\u00a0infants\u00a0in\u00a0Germany. \u00a0\nBundesgesundheitsblatt, \u00a0Gesundheitsforschung, \u00a0Gesundheitsschutz \u00a056:957\u2010984\u00a0\n4.\u00a0 Ogilvie\u00a0I,\u00a0Khoury\u00a0H,\u00a0El\u00a0Khoury\u00a0AC,\u00a0Goetghebeur \u00a0MM\u00a0(2011)\u00a0Burden\u00a0of\u00a0rotavirus\u00a0\ngastroenteritis \u00a0in\u00a0the\u00a0pediatric\u00a0population \u00a0in\u00a0Central\u00a0and\u00a0Eastern\u00a0Europe:\u00a0serotype\u00a0\ndistribution \u00a0and\u00a0burden\u00a0of\u00a0illness.\u00a0Hum\u00a0Vaccin\u00a07:523\u2010533\u00a0\n5.\u00a0 Gleizes\u00a0O,\u00a0Desselberger \u00a0U,\u00a0Tatochenko \u00a0V,\u00a0et\u00a0al.\u00a0(2006)\u00a0Nosocomial \u00a0rotavirus\u00a0infection\u00a0in\u00a0\nEuropean \u00a0countries: \u00a0a\u00a0review\u00a0of\u00a0the\u00a0epidemiology, \u00a0severity\u00a0and\u00a0economic \u00a0burden\u00a0of\u00a0hospital\u2010\nacquired\u00a0rotavirus\u00a0disease.\u00a0Pediatr\u00a0Infect\u00a0Dis\u00a0J\u00a025:12\u201021\u00a0\n6.\u00a0 Velazquez \u00a0FR,\u00a0Luna\u00a0G,\u00a0Cedillo\u00a0R,\u00a0Torres\u00a0J,\u00a0Munoz\u00a0O\u00a0(2004)\u00a0Natural\u00a0rotavirus\u00a0infection\u00a0is\u00a0not\u00a0\nassociated \u00a0to\u00a0intussusception \u00a0in\u00a0Mexican\u00a0children.\u00a0PediatrInfectDisJ \u00a023:S173\u2010S178\u00a0\n7.\u00a0 Anderson \u00a0EJ,\u00a0Weber\u00a0SG\u00a0(2004)\u00a0Rotavirus \u00a0infection\u00a0in\u00a0adults.\u00a0Lancet\u00a0Infectious \u00a0Diseases\u00a04:91\u2010\n99\u00a0\n8.\u00a0 Koch\u00a0J,\u00a0Wiese\u2010Posselt\u00a0M\u00a0(2011)\u00a0Epidemiology \u00a0of\u00a0rotavirus\u00a0infections \u00a0in\u00a0children\u00a0less\u00a0than\u00a05\u00a0\nyears\u00a0of\u00a0age:\u00a0Germany, \u00a02001\u20102008.\u00a0Pediatr\u00a0Infect\u00a0Dis\u00a0J\u00a030:112\u2010117\u00a0\n9.\u00a0 Bresee\u00a0JS,\u00a0Glass\u00a0RI,\u00a0Ivanoff\u00a0B,\u00a0Gentsch\u00a0JR\u00a0(1999)\u00a0Current\u00a0status\u00a0and\u00a0future\u00a0priorities\u00a0for\u00a0\nrotavirus\u00a0vaccine\u00a0development, \u00a0evaluation \u00a0and\u00a0implementation \u00a0in\u00a0developing \u00a0countries. \u00a0\nVaccine\u00a017:2207\u20102222\u00a0\n10.\u00a0 Newman\u00a0RD,\u00a0Grupp\u2010Phelan\u00a0J,\u00a0Shay\u00a0DK,\u00a0Davis\u00a0RL\u00a0(1999)\u00a0Perinatal\u00a0risk\u00a0factors\u00a0for\u00a0infant\u00a0\nhospitalization \u00a0with\u00a0viral\u00a0gastroenteritis. \u00a0Pediatrics \u00a0103:E3\u00a0\n11.\u00a0 Ford\u2010Jones\u00a0EL,\u00a0Wang\u00a0E,\u00a0Petric\u00a0M,\u00a0Corey\u00a0P,\u00a0Moineddin \u00a0R,\u00a0Fearon\u00a0M\u00a0(2000)\u00a0Rotavirus \u2010\nassociated \u00a0diarrhea\u00a0in\u00a0outpatient \u00a0settings\u00a0and\u00a0child\u00a0care\u00a0centers.\u00a0The\u00a0Greater\u00a0Toronto\u00a0\nArea/Peel \u00a0Region\u00a0PRESI\u00a0Study\u00a0Group.\u00a0Pediatric\u00a0Rotavirus \u00a0Epidemiology \u00a0Study\u00a0for\u00a0\nImmunization. \u00a0Arch\u00a0Pediatr\u00a0Adolesc\u00a0Med\u00a0154:586\u2010593\u00a0\n12.\u00a0 Dennehy\u00a0PHM,\u00a0Cortese\u00a0MMM,\u00a0Begue\u00a0REM,\u00a0et\u00a0al.\u00a0(2006)\u00a0A\u00a0Case\u2010Control\u00a0Study\u00a0to\u00a0Determine \u00a0\nRisk\u00a0Factors\u00a0for\u00a0Hospitalization \u00a0for\u00a0Rotavirus \u00a0Gastroenteritis \u00a0in\u00a0U.S.\u00a0Children.\u00a0Pediatr\u00a0Infect\u00a0\nDis\u00a0J\u00a025:1123\u20101131\u00a0\n13.\u00a0 Sharma\u00a0R,\u00a0Hudak\u00a0ML,\u00a0Premachandra \u00a0BR,\u00a0et\u00a0al.\u00a0(2002)\u00a0Clinical\u00a0manifestations \u00a0of\u00a0rotavirus\u00a0\ninfection\u00a0in\u00a0the\u00a0neonatal\u00a0intensive\u00a0care\u00a0unit.\u00a0Pediatr\u00a0Infect\u00a0Dis\u00a0J\u00a021:1099\u20101105\u00a0\n14.\u00a0 Sharma\u00a0R,\u00a0Garrison\u00a0RD,\u00a0Tepas\u00a0JJ,\u00a03rd,\u00a0et\u00a0al.\u00a0(2004)\u00a0Rotavirus \u2010associated \u00a0necrotizing \u00a0\nenterocolitis: \u00a0an\u00a0insight\u00a0into\u00a0a\u00a0potentially \u00a0preventable \u00a0disease?\u00a0J\u00a0Pediatr\u00a0Surg\u00a039:453\u2010457\u00a0\n15.\u00a0 Shim\u00a0JO,\u00a0Son\u00a0DW,\u00a0Shim\u00a0SY,\u00a0Ryoo\u00a0E,\u00a0Kim\u00a0W,\u00a0Jung\u00a0YC\u00a0(2012)\u00a0Clinical\u00a0characteristics \u00a0and\u00a0\ngenotypes \u00a0of\u00a0rotaviruses \u00a0in\u00a0a\u00a0neonatal\u00a0intensive\u00a0care\u00a0unit.\u00a0Pediatrics \u00a0and\u00a0neonatology \u00a053:18\u2010\n23\u00a0\n16.\u00a0 Advisory\u00a0Committee \u00a0on\u00a0Immunization \u00a0Practices\u00a0(ACIP)\u00a0(2006)\u00a0Prevention \u00a0of\u00a0Rotavirus \u00a0\nGastroenteritis \u00a0Among\u00a0Infants\u00a0and\u00a0Children.\u00a0Recommendations \u00a0of\u00a0the\u00a0Advisory\u00a0Committee \u00a0\non\u00a0Immunization \u00a0Practices\u00a0(ACIP).\u00a0MMWR\u00a0Recommendations \u00a0and\u00a0reports\u00a0:\u00a0Centers\u00a0for\u00a0\nDisease\u00a0Control\u00a055:1\u201013\u00a0\n17.\u00a0 Cortese\u00a0MM,\u00a0Parashar\u00a0UD,\u00a0Centers\u00a0for\u00a0Disease\u00a0C,\u00a0Prevention \u00a0(2009)\u00a0Prevention \u00a0of\u00a0rotavirus\u00a0\ngastroenteritis \u00a0among\u00a0infants\u00a0and\u00a0children:\u00a0recommendations \u00a0of\u00a0the\u00a0Advisory\u00a0Committee \u00a0on\u00a0\nImmunization \u00a0Practices\u00a0(ACIP).\u00a0MMWR\u00a0Recommendations \u00a0and\u00a0reports\u00a0:\u00a0Centers\u00a0for\u00a0Disease\u00a0\nControl\u00a0MMWR\u00a058:1\u201025\u00a0\n18.\u00a0 Aidelsburger \u00a0P,\u00a0Grabein\u00a0K,\u00a0Bohm\u00a0K,\u00a0et\u00a0al.\u00a0(2014)\u00a0Cost\u2010effectiveness \u00a0of\u00a0childhood \u00a0rotavirus\u00a0\nvaccination \u00a0in\u00a0Germany. \u00a0Vaccine\u00a032:1964\u20101974\u00a0\n19.\u00a0 Dudareva \u2010Vizule\u00a0S,\u00a0Koch\u00a0J,\u00a0An\u00a0der\u00a0Heiden\u00a0M,\u00a0Oberle\u00a0D,\u00a0Keller\u2010Stanislawski \u00a0B,\u00a0Wichmann \u00a0O\u00a0\n(2012)\u00a0Impact\u00a0of\u00a0rotavirus\u00a0vaccination \u00a0in\u00a0regions\u00a0with\u00a0low\u00a0and\u00a0moderate \u00a0vaccine\u00a0uptake\u00a0in\u00a0\nGermany. \u00a0Human\u00a0vaccines\u00a0&\u00a0immunotherapeutics \u00a08:1407\u20101415\u00a015\u00a0\n\u00a020.\u00a0 Adlhoch\u00a0C,\u00a0Hoehne\u00a0M,\u00a0Littmann\u00a0M,\u00a0et\u00a0al.\u00a0(2013)\u00a0Rotavirus \u00a0vaccine\u00a0effectiveness \u00a0and\u00a0case\u2010\ncontrol\u00a0study\u00a0on\u00a0risk\u00a0factors\u00a0for\u00a0breakthrough \u00a0infections \u00a0in\u00a0Germany, \u00a02010\u20102011.\u00a0Pediatr\u00a0\nInfect\u00a0Dis\u00a0J\u00a032:e82\u201089\u00a0\n21.\u00a0 Patel\u00a0NC,\u00a0Hertel\u00a0PM,\u00a0Estes\u00a0MK,\u00a0et\u00a0al.\u00a0(2009)\u00a0Vaccine\u2010acquired\u00a0Rotavirus \u00a0Infection\u00a0in\u00a0Two\u00a0\nInfants\u00a0with\u00a0Severe\u00a0Combined \u00a0Immunodeficiency. \u00a0Journal\u00a0of\u00a0Allergy\u00a0and\u00a0Clinical\u00a0Immunology \u00a0\n123:731\u00a0\n22.\u00a0 Werther\u00a0RL,\u00a0Crawford \u00a0NW,\u00a0Boniface\u00a0K,\u00a0Kirkwood \u00a0CD,\u00a0Smart\u00a0JM\u00a0(2009)\u00a0Rotavirus \u00a0vaccine\u00a0\ninduced\u00a0diarrhea\u00a0in\u00a0a\u00a0child\u00a0with\u00a0severe\u00a0combined \u00a0immune\u00a0deficiency. \u00a0The\u00a0Journal\u00a0of\u00a0allergy\u00a0\nand\u00a0clinical\u00a0immunology \u00a0124:600\u00a0\n23.\u00a0 American \u00a0Academy \u00a0of\u00a0Pediatrics; \u00a0Committee \u00a0on\u00a0Infectious \u00a0Diseases\u00a0(2009)\u00a0Prevention \u00a0of\u00a0\nrotavirus\u00a0disease:\u00a0updated\u00a0guidelines \u00a0for\u00a0use\u00a0of\u00a0rotavirus\u00a0vaccines.\u00a0Pediatrics \u00a0123:1412 \u20101420\u00a0\n24.\u00a0 European \u00a0Medicines \u00a0Agency;\u00a0Rotarix\u00a0\u2010\u00a0Product\u00a0information \u00a0(15\u00a0May\u00a02014\u00a0(last\u00a0update).\u00a0\nAccessed\u00a0on\u00a028\u00a0May\u00a02014)\u00a0:\u00a0www.ema.europa.eu/docs/de_DE /document_library/EPAR_ \u2010\n_Product_Information/human/000639/WC500054789.pdf \u00a0\n25.\u00a0 European \u00a0Medicines \u00a0Agency;\u00a0RotaTeq\u00a0\u2010\u00a0Product\u00a0information \u00a0(15\u00a0May\u00a02014\u00a0(last\u00a0update),\u00a0\nAccessed\u00a0on\u00a028\u00a0May\u00a02014):\u00a0\nhttp://www.ema.europa.eu/docs /de_DE/document_library/EPAR_ \u2010\n_Product_Information/human/000669/WC500054185.pdf \u00a0\u00a0\n26.\u00a0 Omenaca \u00a0F,\u00a0Sarlangue \u00a0J,\u00a0Szenborn \u00a0L,\u00a0et\u00a0al.\u00a0(2012)\u00a0Safety,\u00a0reactogenicity \u00a0and\u00a0immunogenicity \u00a0\nof\u00a0the\u00a0human\u00a0rotavirus\u00a0vaccine\u00a0in\u00a0preterm\u00a0European \u00a0Infants:\u00a0a\u00a0randomized \u00a0phase\u00a0IIIb\u00a0study.\u00a0\nPediatr\u00a0Infect\u00a0Dis\u00a0J\u00a031:487\u2010493\u00a0\n27.\u00a0 Phua\u00a0KB,\u00a0Lim\u00a0FS,\u00a0Lau\u00a0YL,\u00a0et\u00a0al.\u00a0(2009)\u00a0Safety\u00a0and\u00a0efficacy\u00a0of\u00a0human\u00a0rotavirus\u00a0vaccine\u00a0during\u00a0\nthe\u00a0first\u00a02\u00a0years\u00a0of\u00a0life\u00a0in\u00a0Asian\u00a0infants:\u00a0Randomised, \u00a0double\u2010blind,\u00a0controlled \u00a0study.\u00a0Vaccine\u00a0\n27:5936\u20105941\u00a0\n28.\u00a0 Ruiz\u2010Palacios\u00a0GM,\u00a0Perez\u2010Schael\u00a0I,\u00a0Velazquez \u00a0FR,\u00a0et\u00a0al.\u00a0(2006)\u00a0Safety\u00a0and\u00a0Efficacy\u00a0of\u00a0an\u00a0\nAttenuated \u00a0Vaccine\u00a0against\u00a0Severe\u00a0Rotavirus \u00a0Gastroenteritis. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0354:11\u201022\u00a0\n29.\u00a0 Cheuvart\u00a0BP,\u00a0Friedland \u00a0LRM,\u00a0Abu\u2010Elyazeed\u00a0RM,\u00a0PhD,\u00a0Han\u00a0HHM,\u00a0Guerra\u00a0YM,\u00a0Verstraeten \u00a0TM\u00a0\n(2009)\u00a0The\u00a0Human\u00a0Rotavirus \u00a0Vaccine\u00a0RIX4414\u00a0in\u00a0Infants:\u00a0A\u00a0Review\u00a0of\u00a0Safety\u00a0and\u00a0Tolerability. \u00a0\nPediatric\u00a0Infectious \u00a0Disease\u00a0Journal\u00a0March\u00a02009;28(3):225 \u2010232\u00a028:225\u2010232\u00a0\n30.\u00a0 Vesikari\u00a0T,\u00a0Matson\u00a0DO,\u00a0Dennehy\u00a0P,\u00a0et\u00a0al.\u00a0(2006)\u00a0Safety\u00a0and\u00a0efficacy\u00a0of\u00a0a\u00a0pentavalent \u00a0human\u2010\nbovine\u00a0(WC3)\u00a0reassortant \u00a0rotavirus\u00a0vaccine.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0354:23\u201033\u00a0\n31.\u00a0 Van\u00a0Der\u00a0Wielen\u00a0M,\u00a0Van\u00a0Damme\u00a0P\u00a0(2008)\u00a0Pentavalent \u00a0human\u2010bovine\u00a0(WC3)\u00a0reassortant \u00a0\nrotavirus\u00a0vaccine\u00a0in\u00a0special\u00a0populations: \u00a0A\u00a0review\u00a0of\u00a0data\u00a0from\u00a0the\u00a0Rotavirus \u00a0Efficacy\u00a0and\u00a0\nSafety\u00a0Trial.\u00a0European \u00a0Journal\u00a0of\u00a0Clinical\u00a0Microbiology \u00a0and\u00a0Infectious \u00a0Diseases\u00a027:495\u2010501\u00a0\n32.\u00a0 Goveia\u00a0MG,\u00a0Rodriguez \u00a0ZM,\u00a0Dallas\u00a0MJ,\u00a0et\u00a0al.\u00a0(2007)\u00a0Safety\u00a0and\u00a0efficacy\u00a0of\u00a0the\u00a0pentavalent \u00a0\nhuman\u2010bovine\u00a0(WC3)\u00a0reassortant \u00a0rotavirus\u00a0vaccine\u00a0in\u00a0healthy\u00a0premature \u00a0infants.\u00a0Pediatr\u00a0\nInfect\u00a0Dis\u00a0J\u00a026:1099\u20101104\u00a0\n33.\u00a0 Yen\u00a0C,\u00a0Jakob\u00a0K,\u00a0Esona\u00a0MD,\u00a0et\u00a0al.\u00a0(2011)\u00a0Detection \u00a0of\u00a0fecal\u00a0shedding\u00a0of\u00a0rotavirus\u00a0vaccine\u00a0in\u00a0\ninfants\u00a0following \u00a0their\u00a0first\u00a0dose\u00a0of\u00a0pentavalent \u00a0rotavirus\u00a0vaccine.\u00a0Vaccine\u00a029:4151\u20104155\u00a0\n34.\u00a0 Ruiz\u2010Palacios\u00a0GM,\u00a0Guerrero\u00a0ML,\u00a0Bautista\u2010Marquez\u00a0A,\u00a0et\u00a0al.\u00a0(2007)\u00a0Dose\u00a0Response \u00a0and\u00a0\nEfficacy\u00a0of\u00a0a\u00a0Live,\u00a0Attenuated \u00a0Human\u00a0Rotavirus \u00a0Vaccine\u00a0in\u00a0Mexican\u00a0Infants.\u00a0Pediatrics \u00a0\n120:e253 \u2010e261\u00a0\n35.\u00a0 Department \u00a0of\u00a0Health\u00a0and\u00a0Human\u00a0Services;\u00a0Centers\u00a0for\u00a0Disease\u00a0Control\u00a0and\u00a0Prevention \u00a0(CDC)\u00a0\n(2007)\u00a0Advisory\u00a0Committee \u00a0on\u00a0Immunization \u00a0Practices\u00a0Meeting,\u00a0Atlanta,\u00a0GA,\u00a0October\u00a024\u201325,\u00a0\n2007.\u00a0Record\u00a0of\u00a0the\u00a0Proceedings: \u00a0http://michigan.gov/documents/mdch/ACIP_Min \u2010\nOct_07_219519_7.pdf .\u00a0\n36.\u00a0 Dennehy\u00a0PH,\u00a0De\u00a0Vos\u00a0B,\u00a0Brady\u00a0RC,\u00a0et\u00a0al.\u00a0(2005)\u00a0Comparative \u00a0evaluation \u00a0of\u00a0safety\u00a0and\u00a0\nimmunogenicity \u00a0of\u00a0two\u00a0dosages\u00a0of\u00a0an\u00a0oral\u00a0live\u00a0attenuated \u00a0human\u00a0rotavirus\u00a0vaccine.\u00a0Pediatr\u00a0\nInfect\u00a0Dis\u00a0J\u00a024:481\u2010488\u00a0\n37.\u00a0 Phua\u00a0KB,\u00a0Quak\u00a0SH,\u00a0Lee\u00a0BW,\u00a0et\u00a0al.\u00a0(2005)\u00a0Evaluation \u00a0of\u00a0RIX4414,\u00a0a\u00a0live,\u00a0attenuated \u00a0rotavirus\u00a0\nvaccine,\u00a0in\u00a0a\u00a0randomized, \u00a0double\u2010blind,\u00a0placebo\u2010controlled \u00a0phase\u00a02\u00a0trial\u00a0involving\u00a02464\u00a0\nSingaporean \u00a0infants.\u00a0Journal\u00a0of\u00a0Infectious \u00a0Diseases\u00a0192:6\u201016\u00a016\u00a0\n\u00a038.\u00a0 Smith\u00a0CK,\u00a0McNeal\u00a0MM,\u00a0Meyer\u00a0NR,\u00a0Haase\u00a0S,\u00a0Dekker\u00a0CL\u00a0(2011)\u00a0Rotavirus \u00a0shedding\u00a0in\u00a0\npremature \u00a0infants\u00a0following \u00a0first\u00a0immunization. \u00a0Vaccine\u00a029:8141\u20108146\u00a0\n39.\u00a0 Hsieh\u00a0YC,\u00a0Wu\u00a0FT,\u00a0Hsiung\u00a0CA,\u00a0Wu\u00a0HS,\u00a0Chang\u00a0KY,\u00a0Huang\u00a0YC\u00a0(2014)\u00a0Comparison \u00a0of\u00a0virus\u00a0\nshedding\u00a0after\u00a0lived\u00a0attenuated \u00a0and\u00a0pentavalent \u00a0reassortant \u00a0rotavirus\u00a0vaccine.\u00a0Vaccine\u00a0\n32:1199\u20101204\u00a0\n40.\u00a0 Rivera\u00a0L,\u00a0Pena\u00a0LM,\u00a0Stainier\u00a0I,\u00a0et\u00a0al.\u00a0(2011)\u00a0Horizontal \u00a0transmission \u00a0of\u00a0a\u00a0human\u00a0rotavirus\u00a0\nvaccine\u00a0strain\u2010\u2010a\u00a0randomized, \u00a0placebo\u2010controlled \u00a0study\u00a0in\u00a0twins.\u00a0Vaccine\u00a029:9508\u20109513\u00a0\n41.\u00a0 Payne\u00a0DC,\u00a0Edwards\u00a0KM,\u00a0Bowen\u00a0MD,\u00a0et\u00a0al.\u00a0(2010)\u00a0Sibling\u00a0transmission \u00a0of\u00a0vaccine\u2010derived\u00a0\nrotavirus\u00a0(RotaTeq) \u00a0associated \u00a0with\u00a0rotavirus\u00a0gastroenteritis. \u00a0Pediatrics \u00a0125:438\u2010441\u00a0\n42.\u00a0 Boom\u00a0JA,\u00a0Sahni\u00a0LC,\u00a0Payne\u00a0DC,\u00a0et\u00a0al.\u00a0(2012)\u00a0Symptomatic \u00a0infection\u00a0and\u00a0detection \u00a0of\u00a0vaccine\u00a0\nand\u00a0vaccine\u2010reassortant \u00a0rotavirus\u00a0strains\u00a0in\u00a05\u00a0children:\u00a0a\u00a0case\u00a0series.\u00a0J\u00a0Infect\u00a0Dis\u00a0206:1275 \u2010\n1279\u00a0\n43.\u00a0 Donato\u00a0CM,\u00a0Ch'ng\u00a0LS,\u00a0Boniface\u00a0KF,\u00a0et\u00a0al.\u00a0(2012)\u00a0Identification \u00a0of\u00a0strains\u00a0of\u00a0RotaTeq\u00a0rotavirus\u00a0\nvaccine\u00a0in\u00a0infants\u00a0with\u00a0gastroenteritis \u00a0following \u00a0routine\u00a0vaccination. \u00a0J\u00a0Infect\u00a0Dis\u00a0206:377\u2010383\u00a0\n44.\u00a0 Bowen\u00a0MD,\u00a0Payne\u00a0DC\u00a0(2012)\u00a0Rotavirus \u00a0vaccine\u2010derived\u00a0shedding\u00a0and\u00a0viral\u00a0reassortants. \u00a0\nExpert\u00a0Rev\u00a0Vaccines\u00a011:1311\u20101314\u00a0\n45.\u00a0 Hemming \u00a0M,\u00a0Vesikari\u00a0T\u00a0(2012)\u00a0Vaccine\u2010derived\u00a0human\u2010bovine\u00a0double\u00a0reassortant \u00a0rotavirus\u00a0in\u00a0\ninfants\u00a0with\u00a0acute\u00a0gastroenteritis. \u00a0Pediatr\u00a0Infect\u00a0Dis\u00a0J\u00a031:992\u2010994\u00a0\n46.\u00a0 Monk\u00a0HM,\u00a0Motsney\u00a0AJ,\u00a0Wade\u00a0KC\u00a0(2014)\u00a0Safety\u00a0of\u00a0Rotavirus \u00a0Vaccine\u00a0in\u00a0the\u00a0NICU.\u00a0Pediatrics \u00a0\n133:e1555 \u2010e1560\u00a0\n47.\u00a0 National\u00a0Advisory\u00a0Committee \u00a0on\u00a0Immunization \u00a0(NACI)\u00a0(2010)\u00a0Updated\u00a0Statement \u00a0on\u00a0the\u00a0use\u00a0\nof\u00a0Rotavirus \u00a0Vaccines,. \u00a0Canada\u00a0Communicable \u00a0Disease\u00a0Report\u00a036:1\u201037\u00a0\n48.\u00a0 National\u00a0Centre\u00a0for\u00a0Immunization \u00a0Research\u00a0and\u00a0Surveillance \u00a0(NCIRS)\u00a0(November \u00a02013)\u00a0\nRotavirus \u00a0vaccines\u00a0for\u00a0Australian \u00a0children:\u00a0Information \u00a0for\u00a0immunization \u00a0providers \u00a0(Fact\u00a0\nsheet),\u00a0http://www.ncirs.edu. au/immunisation/fact \u2010sheets/rotavirus \u2010fact\u2010sheet\u2010November \u2010\n2013.pdf .\u00a0In:\u00a0\n49.\u00a0 National\u00a0Health\u00a0and\u00a0Medical\u00a0Research\u00a0Council\u00a0(NHMRC); \u00a0Australian \u00a0Technical \u00a0Advisory\u00a0Group\u00a0\non\u00a0Immunisation \u00a0(2013)\u00a0The\u00a0Australian \u00a0Immunisation \u00a0Handbook. \u00a010th\u00a0ed.\u00a0Canberra: \u00a0\nAustralian \u00a0Government \u00a0Department \u00a0of\u00a0Health,\u00a02013.\u00a0\u00a0\n50.\u00a0 Department \u00a0of\u00a0Health;\u00a0National\u00a0Health\u00a0Service\u00a0England\u00a0(2013)\u00a0Public\u00a0health\u00a0functions \u00a0to\u00a0be\u00a0\nexercised \u00a0by\u00a0NHS\u00a0England;\u00a0Service\u00a0specification \u00a0No.5;\u00a0Rotavirus \u00a0immunisation \u00a0programme, \u00a0\nwww.gov.uk/government/uploads/system/upl oads/attachment_data/file/192981/05_Rotavi\nrus__service_specification_VARIATION__130422.pdf .\u00a0In:\u00a0\n51.\u00a0 Public\u00a0Health\u00a0England\u00a0(2013)\u00a0Rotavirus. \u00a0In:\u00a0Green\u00a0Book;\u00a0Immunisation \u00a0against\u00a0infectious \u00a0\ndisease.\u00a0S\u00a0329\u2010342\u00a0\n52.\u00a0 Heininger \u00a0U\u00a0BP,\u00a0Huppertz \u00a0HI,\u00a0Klein\u00a0R,\u00a0Kinet\u00a0M,\u00a0Korenke\u00a0G\u00a0Ch,\u00a0(2013)\u00a0\u00dcberwachung \u00a0von\u00a0\nFr\u00fchgeborenen \u00a0im\u00a0Rahmen\u00a0der\u00a0Grundimmunisierung. \u00a0Monatsschr \u00a0Kinderheilkd \u00a0161:946\u2010949\u00a0\n53.\u00a0 Stumpf\u00a0KA,\u00a0Thompson \u00a0T,\u00a0Sanchez\u00a0PJ\u00a0(2013)\u00a0Rotavirus \u00a0vaccination \u00a0of\u00a0very\u00a0low\u00a0birth\u00a0weight\u00a0\ninfants\u00a0at\u00a0discharge \u00a0from\u00a0the\u00a0NICU.\u00a0Pediatrics \u00a0132:e662 \u2010665\u00a0\n54.\u00a0 Rogowski \u00a0JA,\u00a0Staiger\u00a0D,\u00a0Patrick\u00a0T,\u00a0Horbar\u00a0J,\u00a0Kenny\u00a0M,\u00a0Lake\u00a0ET\u00a0(2013)\u00a0Nurse\u00a0staffing\u00a0and\u00a0NICU\u00a0\ninfection\u00a0rates.\u00a0JAMA\u00a0pediatrics \u00a0167:444\u2010450\u00a0\n55.\u00a0 Mitteilung \u00a0der\u00a0Kommission \u00a0f\u00fcr\u00a0Krankenhaushygiene \u00a0und\u00a0Infektionspr\u00e4vention \u00a0beim\u00a0Robert\u00a0\nKoch\u2010Institut\u00a0(2007)\u00a0Empfehlung \u00a0zur\u00a0Pr\u00e4vention \u00a0nosokomialer \u00a0Infektionen \u00a0bei\u00a0\nneonatologischen \u00a0Intensivpflegepatienten \u00a0mit\u00a0einem\u00a0Geburtsgewicht \u00a0unter\u00a01500g.\u00a0\nBundesgesundheitsbl \u00a050:1265\u20101303\u00a0\n\u00a0", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}